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ABSTRACT 
The synthesis of four homologous anthraquinones (AQ I-IV) bearing increasing lengths 
of polyethylene glycol (PEG) side chains and their binding to AT- and GC-rich DNA hairpins 
are reported.  The molecules were designed such that the cationic charge is at a constant position 
and the ethylene glycol units chosen to allow significant increases in size with minimal changes 
in hydrophobicity.  The mode and affinity of binding were assessed using circular dichroism 
(CD), nuclear magnetic resonance (NMR), surface plasmon resonance (SPR), and isothermal ti-
tration calorimetry (ITC).  The binding affinity decreased as the AQ chain length increased along 
the series with both AT- and GC-rich DNA.  ITC measurements showed that the thermodynamic 
parameters of AQ I-IV binding to DNA exhibited significant enthalpy-entropy compensation.  
The enthalpy became more favorable while the entropy became less favorable.  The correlation 
between enthalpy and entropy may involve not only the side chains, but also changes in the bind-
ing of water and associated counterions and hydrogen bonding.   
The interactions of AQ I-IV with GC-rich DNA have been studied via molecular dynam-
ics (MD) simulations.  The geometry, conformation, interactions, and hydration of the complexes 
were examined.  As the side chain lengthened, binding to DNA reduced the conformational 
space, resulting in an increase in unfavorable entropy.  Increased localization of the PEG side 
chain in the DNA groove, indicating some interaction of the side chain with DNA, also contrib-
uted unfavorably to the entropy.  The changes in free energy of binding due to entropic consider-
ations (-3.9 to -6.3 kcal/mol) of AQ I-IV were significant.   
The kinetics of a homologous series of anthraquinone threading intercalators, AQT I-IV 
with calf thymus DNA was studied using the stopped-flow.  The threading mechanisms of the 
anthraquinones binding to DNA showed sensitivity to their side chain length.  Fitting of the ki-
netic data led to our proposal of a two step mechanism for binding of AQT I, bearing the short-
est side chain, and a three step mechanism for binding of the three longer homologs.  Binding 
involves formation of an externally bound anthraquinone-DNA complex, followed by intercala-
tion of the anthraquinone for AQT I-IV, then isomerization to another complex with similar 
thermodynamic stability for AQT II-IV.   
INDEX WORDS: Anthraquinone amide, Polyethylene glycol, Homologous, DNA, Hairpin, AT-
rich, GC-rich, ct-DNA, Intercalate, Enthalpy-entropy compensation, Surface plasmon 
resonance, Isothermal titration calorimetry, Circular dichroism, Nuclear magnetic reso-
nance, Molecular dynamics simulation, Hydration, Kinetics 
 BIOPHYSICAL CHARACTERIZATION OF THE BINDNG OF HOMOLOGOUS 
ANTHRAQUINONE AMIDES TO DNA 
 
 
 
by 
 
 
 
 
SHIRLENE JACKSON BECKFORD 
 
 
 
 
 
 
 
A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
in the College of Arts and Sciences 
Georgia State University 
2012 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Shirlene Jackson Beckford 
2012
 BIOPHYSICAL CHARACTERIZATION OF THE BINDNG OF HOMOLOGOUS 
ANTHRAQUINONE AMIDES TO DNA 
 
by 
 
 
SHIRLENE JACKSON BECKFORD 
 
 
 
Committee Chair:  Dabney W. Dixon 
 
Committee: David Wilson 
Donald Hamelberg 
 
 
Electronic Version Approved: 
 
 
Office of Graduate Studies 
College of Arts and Sciences 
Georgia State University 
August 2012 
i 
 
DEDICATION 
To Garfield and Jewelle 
You have given me strength and purpose to complete this project. 
v 
 
 
ACKNOWLEDGEMENTS 
I would like to thank God, who has given me this opportunity and the strength to com-
plete this project.   
Thanks to my advisor, Dr. Dabney Dixon, for the guidance, patience, and motivation that 
she was able to provide.  She has been a constant source of intellectual stimulation throughout 
the years and a reminder of the importance of interpersonal relationships.    
To Neval, Yu, Joy, and Elizabeth, it goes without saying, that the dynamic in our lab is 
one of friendship and trust.  Thanks for the constant support and humor that you have provided, 
in helping me find my way though graduate school.     
I would also like to thank my family, Mom, Dad, my brothers and sisters for the joy, per-
spective, and support they bring. I know you are truly happy about the completion of my doctoral 
studies.     
Special thanks to my committee advisors, Dr. Wilson and Dr. Hamelberg.  Thanks for 
your time and helpful discussions in helping me to complete my studies.  I also want to say 
thanks to Dr. Gadda who was very instrumental in collecting and interpreting the kinetic data. 
vi 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ............................................................................................. v 
LIST OF TABLES ........................................................................................................... ix 
LIST OF FIGURES .......................................................................................................... x 
1 OVERVIEW OF SMALL MOLECULES BINDING TO DNA ............................ 1 
1.1 DNA as a Target for Drug Design ..................................................................... 1 
1.2 Binding of Small Molecules to DNA .................................................................. 1 
1.3 Mode of Binding of Small Molecules to DNA ................................................... 2 
1.3.1 Minor Groove Binding .................................................................................... 2 
1.3.2 Classical Intercalators .................................................................................... 5 
1.4 The Anthraquinone Drug Class ......................................................................... 6 
1.4.1 Kinetic Studies on Threading Anthraquinones ........................................... 11 
1.4.2 Energetics of Anthraquinone Binding to DNA ........................................... 13 
1.5 Research Goals .................................................................................................. 16 
1.6 References .......................................................................................................... 20 
2 EFFECT OF SIDE CHAIN LENGTH ON DNA BINDING AFFINITY............ 27 
2.1 Work to be published ........................................................................................ 27 
2.1.1 Abstract .......................................................................................................... 27 
2.1.2 Introduction ................................................................................................... 28 
2.1.3 Materials and Methods ................................................................................. 30 
vii 
2.1.4 Results............................................................................................................ 39 
2.1.5 Discussion...................................................................................................... 43 
2.1.6 Conclusions. .................................................................................................. 50 
2.2 Unpublished Work. ........................................................................................... 52 
2.2.1 NMR: Determination of the Binding Mode of AQ to GC-rich DNA. ......... 52 
2.2.2 CD: Derivation of the Binding Constant of AQ II binding to DNA ........... 52 
2.2.3 SPR: Calculated RU versus Observed RU versus Fitted RU values. .......... 55 
2.2.4 ITC: Determination of the heats of dilution for AQ I-IV. ........................... 56 
2.3 References .......................................................................................................... 82 
3 SYNTHESIS OF DICATIONIC ANTHRAQUINONE AMIDES ....................... 90 
3.1 Introduction ....................................................................................................... 90 
3.2 Materials and Methods ..................................................................................... 91 
3.2.1 Synthesis of AQD I. ....................................................................................... 91 
3.2.2 Synthesis of AQD II. ..................................................................................... 92 
3.2.3 Synthesis of AQD III..................................................................................... 93 
3.2.4 Synthesis of AQD IV. .................................................................................... 94 
3.2.5 Isothermal Titration Calorimetry (ITC). ...................................................... 94 
3.3 Results and Discussion ...................................................................................... 95 
3.4 References ........................................................................................................ 107 
viii 
4 MOLECULAR DYNAMICS OF ANTHRAQUINONE DNA INTERCALATORS 
WITH POLYETHYLENE GLYCOL SIDE CHAINS .......................................... 108 
4.1 Direct Copy of Published Work ..................................................................... 108 
4.1.1 Abstract ........................................................................................................ 108 
4.1.2 Introduction ................................................................................................. 108 
4.1.3 Materials and Methods ............................................................................... 111 
4.1.4 Results and Discussion ............................................................................... 115 
4.1.5 Conclusions. ................................................................................................ 123 
4.2 Unpublished Data. ........................................................................................... 124 
4.3 References ........................................................................................................ 134 
5 INVESTIGATION OF THE KINETICS OF A SERIES OF THREADING 
ANTHRAQUINONE INTERCALATORS ............................................................ 141 
5.1 Introduction ..................................................................................................... 141 
5.2 Work to be published ...................................................................................... 145 
5.2.1 Abstract ........................................................................................................ 145 
5.2.2 Introduction ................................................................................................. 145 
5.2.3 Results and Discussion ............................................................................... 147 
5.2.4 Conclusion ................................................................................................... 151 
5.2.5 Supplementary Information ....................................................................... 162 
5.3 References ........................................................................................................ 164 
ix 
LIST OF TABLES 
Table 2.1: Thermodynamic data for the interaction of AQ I-IV with DNA at 25 
o
C ..... 81 
Table 2.2: Kaleidagraph fitting of the SPR data from the binding of AQ I-IV to AT- and   
                  GC-rich DNA hairpins. ................................................................................... 81 
Table 2.3: Results from the dilution of AQ I-IV in MES10 buffer. ................................ 81 
Table 3.1: Binding parameters of AQD I-IV as determined by Isothermal Titration   
                  Calorimetry. .................................................................................................. 107 
Table 4.1: Entropy change of the AQ I-IV side chain when free in solution and bound to   
                  DNA. ............................................................................................................. 134 
Table 4.2: Hydration of the AQ IV side chain when free in solution and bound to DNA.  
                  ....................................................................................................................... 134 
Table 4.3: Hydration of the oxygens in AQ I-IV when free in solution and bound to   
                  DNA. ............................................................................................................. 134 
Table 5.1: Kinetic constants for the anthraquinone-DNA interaction ........................... 163 
 
x 
LIST OF FIGURES 
Figure 1.1: Structures of minor groove binding ligands .................................................. 31 
Figure 1.2: Structures of classical intercalating ligands .................................................. 32 
Figure 1.3: Structures of threading intercalating ligands. ................................................ 32 
Figure 2.1: Anthraquinone intercalators, AQ I-IV, used in this study. ........................... 73 
Figure 2.2: Downfield region of the 
1
H NMR spectra of AT-rich DNA hairpin. ........... 74 
Figure 2.3: CD spectral titration of AQ II with 10 µM AT-rich DNA hairpin in MES10   
                   buffer, pH 6.24 and 25 
o
C. ............................................................................. 75 
Figure 2.4: CD spectral titration of AQ II with 10 µM GC-rich DNA hairpin in MES10   
                   buffer, pH 6.24 and 25 
o
C. ............................................................................. 76 
Figure 2.5: SPR sensograms for AQ II with AT-rich and GC-rich DNA. ...................... 77 
Figure 2.6: ITC curve for the binding of AT-rich DNA hairpin to a) AQ I, b) AQ II, c)   
                   AQ III, and d) AQ IV. .................................................................................. 78 
Figure 2.7: Entropy-enthalpy compensation plot for drug-DNA binding data. ............... 79 
Figure 2.8: Plot of the a) hydrophobicity (Xlog P) and b) rotatable bonds of various   
                   intercalators in the literature as a function of their binding constant. ............ 79 
Figure 2.9 (S1):
 1
H NMR spectrum of AQ I in chloroform. ........................................... 80 
Figure 2.10 (S2): 
1
H NMR spectrum of AQ II in chloroform. ........................................ 81 
Figure 2.11 (S3): 
1
H NMR spectrum of AQ III in chloroform. ...................................... 82 
Figure 2.12 (S4): 
1
H NMR spectrum of AQ IV in chloroform. ...................................... 83 
Figure 2.13 (S5): 
13
C NMR spectrum of AQ I in chloroform. ........................................ 84 
Figure 2.14 (S6): 
13
C NMR spectrum of AQ II in chloroform........................................ 85 
Figure 2.15 (S7):
 13
C NMR spectrum of AQ III in chloroform. ..................................... 86 
Figure 2.16 (S8): 
13
C NMR spectrum of AQ IV in chloroform. ..................................... 87 
xi 
Figure 2.17 (S9): SPR sensograms for AQ I with AT-rich and GC-rich DNA. ............. 88 
Figure 2.18 (S10): SPR sensograms for AQ III with AT-rich and GC-rich DNA. ........ 89 
Figure 2.19 (S11): SPR sensograms for AQ IV with AT-rich and GC-rich DNA. ........ 90 
Figure 2.20 (S12): ITC curve for the binding of AT-rich DNA hairpin to a) AQ I, b) AQ   
                    II, c) AQ III, and d) AQ IV. ........................................................................ 91 
Figure 2.21 (S13): Downfield region of the 
1
H NMR spectra of GC-rich DNA hairpin   
                    with AQ II. ................................................................................................... 92 
Figure 2.22 (S14): ITC curve for the dilution of 300 µM a) AQ I, b) AQ II, c) AQ III,   
                    and d) AQ IV in MES10 buffer. ................................................................... 93 
Figure 3.1: Anthraquinone intercalators, AQD I-IV, used in this study. ...................... 110 
Figure 3.2: 
1
H NMR spectrum of AQD I in chloroform ............................................... 112 
Figure 3.3: 
1
H NMR spectrum of AQD II in chloroform ............................................. 113 
Figure 3.4: 
1
H NMR spectrum of AQD III in chloroform ............................................ 114 
Figure 3.5: 
1
H NMR spectrum of AQD IV in chloroform ............................................ 115 
Figure 3.6: 
13
C NMR spectrum of AQD I in chloroform .............................................. 116 
Figure 3.7: 
13
C NMR spectrum of AQD II in chloroform ............................................ 117 
Figure 3.8: 
13
C NMR spectrum of AQD III in chloroform ........................................... 118 
Figure 3.9: 
13
C NMR spectrum of AQD IV in chloroform ........................................... 119 
Figure 3.10: ITC heat of dissociation curves for a) AQD I, b) AQD II, c) AQD III, and   
                     d) AQD IV ................................................................................................. 119 
Figure 4.1: (A) Chemical structures of anthraquinone amides, AQ I – IV ................... 139 
Figure 4.2: Representative snapshot of the interaction of AQ I with the DNA hairpin. 139 
Figure 4.3: Analysis of the binding of AQ I (left) and AQ IV (right) to DNA; data are  
xii 
                    ..................................................................................................................... 140 
Figure 4.4: Composite of 250 snapshot geometries of AQ I (top) and AQ IV (bottom)   
                   between 10 to 50 ns for the free (left) and bound (right) ligands. ............... 140 
Figure 4.5: Analysis of localization of AQ II-IV side chain in the DNA minor groove;   
                    data are presented as a function of the distance between the second oxygen   
                    of the side chain and DG5:O2 of the DNA. ................................................ 141 
Figure 4.6: Analysis of the side chain conformation of AQ I-IV; data are presented as a   
                    function of distances between the R2NH2
+
 group and terminal methyl of the   
                    side chain. ................................................................................................... 141 
Figure 4.7:  Subset of AQ IV structures with the side chain localized in the DNA groove   
                     (distances of less than 5 Å between second oxygen of the side chain and   
                     DG5:O2 of the DNA)................................................................................. 141 
Figure 4.8: Minor groove view of the hydration of the AQ I-DNA complex (left) and   
                   AQ IV-DNA complex (right). ..................................................................... 142 
Figure 4.9 (S1): Infrared spectrum of neat AQ I. .......................................................... 143 
Figure 4.10 (S2): 
1
H NMR spectrum of AQ I in CDCl3. .............................................. 143 
Figure 4.11 (S3): 2D ROESY NMR spectrum of AQ I. ............................................... 144 
Figure 4.12 (S4):  The NH-CO ω-dihedral angle as a function ..................................... 145 
Figure 4.13 (S5): Probability plot of the AQ-NHCO Φ-dihedral angle for the free AQ I   
                    ligand (top).  Conversion of the probability plot to its corresponding free   
                    energy profile (bottom). .............................................................................. 145 
Figure 4.15: Hydration of AQ-ligand. ........................................................................... 146 
Figure 4.14 (S6): Analysis of the binding of AQ II (left) and AQ III (right) to DNA;   
xiii 
                    data are presented as a function of time. ..................................................... 146 
Figure 5.1: Threading anthraquinone intercalators, AQT I - AQT IV used in this study.  
                   ...................................................................................................................... 167 
Figure 5.2: Fluorescence spectral titration of ct-DNA with 3.3 µM AQT IV in MES10   
                   buffer, 0.15 M NaCl, pH 6.24 and 25 
oC (λex:354 nm; λem:536 nm). .......... 168 
Figure 5.3: Dependence of the observed rates of the AQT IV/ct-DNA system on the   
                   concentration of DNA in MES10 buffer, pH 6.4, 0.15 M NaCl at 25 
o
C. ... 169 
Figure 5.4: Dependence of the observed rates of the AQT I/ct-DNA system on the   
                   concentration of DNA in MES10 buffer, pH 6.4, 0.15 M NaCl at 25 
o
C. ... 170 
Figure 5.5 (S1): Fluorescence spectral titration of ct-DNA with 3.3 µM AQT I in   
                   MES10 buffer, 0.15 M NaCl, pH 6.24 and 25 
oC (λex: 354 nm; λem:536 nm).  
                   ...................................................................................................................... 171 
Figure 5.6 (S2): Fluorescence spectral titration of ct-DNA with 3.3 µM AQT III in   
                  MES10 buffer, 0.15 M NaCl, pH 6.24 and 25 
oC (λex: 354 nm; λem:536 nm).  
                   ...................................................................................................................... 172 
Figure 5.7 (S3): Fluorescence spectral titration of ct-DNA with 3.3 µM AQT III in   
                  MES10 buffer, 0.15 M NaCl, pH 6.24 and 25 
oC (λex: 354 nm; λem:536 nm).  
                  ....................................................................................................................... 173 
Figure 5.8 (S4): Dependence of the observed rates of the AQT II/ct-DNA system on the   
                  concentration of DNA in MES10 buffer, pH 6.4, 0.15 M NaCl at 25 
o
C. .... 174 
Figure 5.9 (S5): Dependence of the observed rates of the AQT III/ct-DNA system on   
                  the concentration of DNA in MES10 buffer, pH 6.4, 0.15 M NaCl at 25 
o
C                   
                  ....................................................................................................................... 175 
1 
1 OVERVIEW OF SMALL MOLECULES BINDING TO DNA 
1.1 DNA as a Target for Drug Design  
The discovery and development of new therapeutics has been a topic of interest for sev-
eral decades.  Technology and innovation have brought about the advent of new high throughput 
screening methods 
1-3
 and the application of both rational 
4-6
, and structure based drug design 
7-9
 
in searching for potentially interesting therapeutic agents and to the understanding of metabolic 
processes.  One major aspect of drug discovery in both academia and industry has been the spe-
cific molecular recognition of gene sequences by ligands 
10-14
.    
The design of small molecules that selectively target DNA has led to the development of 
many anticancer, antibiotic, antiprotozoal and antiviral drugs 
12, 15-21
.  These drugs are generally 
thought to exert their biological activities through binding with target DNA sequences and sub-
sequently interference with DNA replication and transcription, and inhibition of gene expression. 
The development of new molecules that can target specific DNA sequences with high binding 
affinities requires elucidation of their molecular recognition patterns, and the driving forces that 
gives rise to their binding affinities as well as their binding mechanisms.   
1.2 Binding of Small Molecules to DNA   
Small molecules that bind to DNA have proven that they can be effective therapeutic 
agents 
18, 22-23
; however, one of the most challenging goals in this area is the design of molecules 
which bind to DNA with high selectivity and large association constants.  There are four general 
factors that are generally considered when designing small molecules that target DNA 
16, 24-29
; 
first, the structural properties of the molecule which include its stereoelectronic properties and 
attached functional groups that promote different types of bonding.  Structure activity relation-
2 
ships studies are generally used for optimization.  A second important consideration is how the 
spatial characteristics of the molecule (configuration and conformation) affect its interactions 
with DNA.  Third, the physiochemical properties of the molecules need to be considered.  These 
include their solubility, ionization, partition coefficients and phase behaviors which in part dic-
tate the binding interaction of the molecule, as well as the transport and activity of the drug in the 
body.  Fourth, the dose and effective drug concentration are important in drug-DNA interactions 
since they are important in qualifying a drug as both potent and effective.  Work on the interac-
tions of small molecules with DNA continues to advance with developments in molecular biolo-
gy, chemical synthesis, biophysical methods, computational capabilities, and analytical instru-
mentation.  
1.3 Mode of Binding of Small Molecules to DNA  
Small molecules generally bind to DNA covalently or non-covalently by through π-
stacking, hydrogen bond, electrostatic and hydrophobic interactions. These non-covalent binders 
associate by major or minor groove binding as well as intercalation and outside binding. 
1.3.1 Minor Groove Binding   
Groove binding occurs when a molecule fits into the DNA groove and interacts with the 
base pairs on the floor and walls of the DNA.  The functional groups of the DNA bases are ac-
cessible in the grooves and thus, binding of a molecule is significantly more selective than inter-
calation because it makes direct contact with more base pairs and their functional groups 
30
.  
Both the major and minor groove exhibit different electrostatic potential, hydrogen bonding 
characteristics, steric effects, micro-environmental polarity, and hydration 
30
.  These characteris-
tics vary depending on the DNA sequence.  The DNA structure and conformation are also de-
pendent on the sequence.  The major groove is wide and accessible and usually accommodates 
3 
proteins.  In contrast, the minor groove is much smaller and binds mostly small molecules and 
displays specific contacts with the narrower groove.  Typical minor groove binders include the 
polyamides, the bis-benzimidazoles such as Hoechst 33258, the diarylamidines (DAPI, berenil, 
and pentamidine), distamycin A, and netropsin, (Figure 1). 
In general, minor groove binders contain unfused aromatic rings and are linked by bonds 
that allow rotation of the molecule to fit the curvature of the DNA groove 
31
.  Their flexibility 
allows the molecule to twist appropriately to complement the shape to the DNA groove, while 
promoting favorable placement of its functional groups, through the formation of H-bonds, elec-
trostatic interactions and van der Waals contacts in the groove.  Minor groove binders usually 
favor AT-rich sequences because the amino group of guanine and the carbonyl oxygen of cyto-
sine in GC-rich sequences sterically inhibit the ligand’s interaction with these bases 32.  In addi-
tion, the DNA minor groove is narrower in AT-rich sequences compared to GC-rich sequences, 
thus, allowing the small molecule to make better van der Waals contacts with the walls of the 
groove.  The electrostatic potential of the AT-rich minor groove is more negative than that in the 
GC-rich minor groove 
33
.  Because most minor groove binders are positively charged, this also 
promotes binding at AT-rich sites.  Small molecules typically bind to the DNA minor groove 
with binding affinities in the order of ~10
5
 – 109 M, and usually cause little disturbance of the 
DNA structure 
31
. 
Interaction of groove binders with DNA has shown a wide range of biological activity in-
cluding antitumor, antiviral, antifungal and antimicrobial effects 
34
.  Diarylamidines are effective 
in the treatment of trypanosomiasis and leishmaniasis 
16, 35
.  Some examples include DAPI, 
berenil, stilbamidine, and pentamidine.  DAPI targets AT-rich regions of duplex DNA, binding 
to the minor groove with its phenyl and indole rings parallel to the groove walls covering the 
4 
three-base pair sequence ATT 
18
.  However, DAPI has numerous undesirable side effects, so its 
use in the clinic as an anti-microbial has been limited 
18
.  Berenil also binds with high affinity to 
ATT-DNA sequences 
18
.  It is widely used in veterinary medicine for the treatment of 
trypanosomaisis
36
.  Pentamidine also preferentially target AT-rich sequences in the DNA minor 
groove 
18
.  It is active against a variety of protozoa including Pneumocystis carinii; however, it 
displays side effects such as nephrotoxicity, cardiotoxicity, and hepatotoxiticy 
37-39
.  Pentamidine 
is also known to inhibit oncogenic PRL phosphatases 
40
. These proteins play an important role in 
many cancers and, as such, can be therapeutic targets for diseases such as pancreatic cancer 
40-42
.  
Most antitumor drugs bind non-specifically to DNA, causing damage to normal cells.  However, 
minor groove binders usually targets AT-rich regions of DNA with high specificity.   
Distamycin A is another minor groove binding agent that displays significant biological 
activities.  The drug is a naturally occurring tripyrrole peptide, isolated from the cultures of 
Streptomyces distallicus 
43
.  It has been subsequently synthesized both in solution and on solid 
phase 
44
.  This antibiotic has  antibacterial and antiviral activities; however, it is inactive as an 
antitumor agent 
45
.  The most important antiviral effects are directed against DNA-containing 
viruses (herpes simplex, herpes zoster, and vaccine virus); it is not active against RNA virus.  
Distamycin A has also been shown to possess antiprotozoal activity against Plasmodium falcipa-
rum 
46
.  Distamycin selectively binds to the minor groove of A/T-containing DNA; each NH 
group in the amide unit participates in hydrogen bonding with a thymine O2 and/or an adenine 
N3 
47
.  Modifications have since been made to the methylpyrrole groups which bind to DNA as a 
stacked dimer and alters the sequence recognition pattern from an AT to GC base-pair 
48
.  
5 
1.3.2 Classical Intercalators 
Leonard Lerman was the first to propose the intercalation model for a ligand binding to 
DNA in the early 1960s 
49
.  Intercalators possess a common structural feature which is an ex-
tended, electron-deficient planar aromatic ring structure.  The almost coplanar arrangement of 
the DNA bases allows intercalation of the planar aromatic ring of the intercalator in between the 
bases.  Although intercalation occurs without interfering with the hydrogen bonding of the base 
pairs, this binding mode requires extensive conformational change of the DNA double helix 
50
.  
The DNA has to unwind so that the intercalator fits between the two base pairs.  This unwinding 
leads to a lengthening of the helix by approximately 3.4 Å, which subsequently causes signifi-
cant conformational changes of some involved sugar moieties 
31
.  It has also been shown that 
during unwinding, the sugar group may be changed from C2'-endo to C3'-endo.  Unwinding and 
lengthening of the DNA increases the phosphate spacing and therefore causes a decrease in the 
charge density along the DNA backbone.  The decrease in charge density leads to a release of 
condensed counterions from the grooves and provides an energetically favorable contribution to 
the free energy of binding.  Intercalators also establish favorable electrostatic, dipole-dipole, van 
der Waals, and π-stacking interactions with the DNA.  The favorable contributions usually result 
in association constants of 10
4
 to 10
6
 M
-1 31
.   
Most intercalators have a variety of chemical substituents, including sugar rings or pep-
tide groups.  These substituents have a major role in the DNA sequence specificity, thermody-
namic stability and structural orientation of the intercalator.  Substituents usually occupy the 
DNA grooves and form favorable non-covalent contacts such as electrostatic interactions, van 
der Waals interactions, hydrophobic interactions and hydrogen-bonding interactions.  For more 
complex intercalators, the functional group substituents can give rise to direct sequence readout 
6 
and hence sequence selectivity 
51-52
.  Typical examples of intercalators include ethidium , 
daunomycin, proflavin, acridines, m-AMSA, and actinomycin (Figure 2). 
The main interest in intercalating drugs lies in their antitumor properties, several interca-
lating molecules have shown anticancer properties.  The mechanism by which these molecules 
act is not fully understood, however, it is generally accepted that these drugs act as cellular 
topoisomerase I and II inhibitors 
53
.  Intercalators currently in clinical use for antitumor treatment 
include the anthracycline antibiotics adriamycin and daunomycin, mitoxantrone, ametantrone, 
and amsacrine 
54-59
. 
The anthraquinone related intercalator, daunomycin, is probably the best studied interca-
lating drug with over 20 high resolution structures known.  Daunomycin binds to DNA with its 
long axis almost perpendicular to the long axis of the adjacent base pairs 
60
.  The amino sugar 
group, attached to ring A, resides in the minor groove and is stabilized by van der Waals interac-
tions and hydrogen bonds.  The hydroxyl group on ring A acts as a hydrogen donor and acceptor 
which gives rise to a favorable enthalpy of intercalation as well as the specificity and orientation 
of binding.  The minor groove of the DNA is filled with the amino sugar, as well as ring A which 
causes bound water molecules and ions to be expelled.  This gives rise to a favorable binding en-
tropy.  Ring D of daunomycin occupies the major groove.     
1.4 The Anthraquinone Drug Class  
Anthraquinones form the basis of several anticancer drugs including daunomycin, doxo-
rubicin, mitoxantrone and ametantrone 
54-59
.  They exert their cytotoxic activities through several 
modes 
57
.  First, they interact with DNA, preferentially at 5'-pyrimidine-purine- 3' GC-rich sites.  
This causes significant conformational changes in the DNA leading to inhibited synthesis of the 
DNA.  Second, anthraquinone intercalation may produce damaging free radicals or radical-ion 
7 
intermediates as a consequence of its redox properties.  This may lead to DNA damage or lipid 
peroxidation. Third, they can cause inhibition of topoisomerase II activity, leading to DNA dam-
age or induction of apoptosis.  Fourth, certain derivatives can cause DNA cross-linking or alkyla-
tion.  Fifth, examples of interference with DNA unwinding or DNA strand separation and hel-
icase activity are known.  Finally, direct membrane effects have been shown in some instances. 
Numerous high-resolution crystal structures of anthraquinones binding to duplex DNA 
are in the Nucleic Acids Structure Database 
61-69
.  The classical feature of anthraquinone-DNA 
interactions is exhibited by adriamycin and daunomycin 
62
.  Adriamycin, which has been used in 
the clinic for more than 30 years and is still a widely used cancer chemotherapeutic, intercalates 
into DNA with rings B and C between the adjacent base pairs of DNA.  The drug intercalates at a 
pyrimidine-purine step with a preference for the CG sequence, with its sugar moiety interacting 
with the minor groove of DNA 
62
.  Daunomycin, which differs from adriamycin by only a hy-
droxyl group displays a similar binding mode 
62
.  However, the molecules have significant dif-
ferences in their binding interactions, including sequence specificities and solvent interactions.   
The DNA binding properties and biological activities of anthraquinone intercalators are 
significantly affected by the different substituents of the planar ring system 
22, 70-83
.  These 
changes mostly involve structural alterations such as the number and position of substituents 
70-
71, 76, 79
, the number of charges 
71
, and variation in the type of substituents 
72-73, 79, 82
.   These prop-
erties have been shown to significantly affect their binding modes and affinity to DNA, as well 
as their biological activities 
70-71, 76-83
, which are discussed below.   
 In early work, Tanious et al. found that anthraquinone derivatives with substituents in the 
1,4 and 1,8 positions intercalated classically in DNA, while 1,5 derivatives were threading 
intercalators, with one side chain in each groove 
70
.  This was in line with previous molecular 
8 
modeling work of Neidle and colleagues 
76
.  Spectrophotometric titration showed that the bind-
ing affinities of substituted amido-anthraquinones with duplex DNA was in the order 1,5-bis > 
1,4-bis > 1,8-bis > monosubstituted anthraquinones 
84
.  The 1,5-isomer bearing alkyl-amino side 
chains had an affinity for duplex DNA of 3.97 x 10
6 
M
-1
, two and a half times that of the analo-
gous monosubstituted anthraquinone.   
2,6-Amidoanthraquinones bearing substituents such as morpholino-, diethylamino-, and 
piperidino- groups were shown to increase the melting temperature of duplex DNA in proportion 
to the amount of ligand added 
79
.  Diethylamino and piperidino analogs showed a higher Tm than 
the morpholino analog, which was assumed to arise from the reduced basicity of the side chain.  
Diethyl hydroxyamines showed lower melting temperatures and computed higher binding en-
thalpies than the piperidine analogues indicating a lower binding constant with the DNA plasmid 
used.  Molecular modeling studies suggested this might be due to the inability of the diethyl 
hydroxy amino groups to follow the helical coil of the DNA grooves, resulting in decreased in-
teraction.    
Breslin et al. have described the binding of mono-, di-, and tetracationic anthraquinones 
to DNA
81
.  They have shown that both monocationic and dicationic anthraquinones bind to DNA 
via an intercalative mode, using NMR and UV/VIS studies.  However, the tetracationic 
anthraquinone investigated binds primarily to the minor groove of duplex DNA.  Docking stud-
ies have shown that in this mode, the positively charged ammonium groups can be placed within 
van der Waals contact of the negatively charged phosphate group. As such, significant electro-
static contacts are made, stabilizing the AQ-DNA groove bound complex.   
Our group has previously demonstrated that binding affinity depends on side chain length 
of a homologous series of anthraquinone threading intercalators, using surface plasmon reso-
9 
nance 
82
.  Binding constants of anthraquinone bearing 1-4 ethylene glycol units in their side 
chain were investigated with AT and GC rich sequences.  The binding constant for the 2,6-
anthraquinone with one ethylene glycol unit and AT rich DNA was 7.6 x 10
5 
M
-1
, four times that 
of the largest member of the homologous series.  These results were consistent with melting 
temperature studies with the first member of the homologous series melting at ~ 7 
o
C higher than 
the last member.  The effect of the side chain may be the result of a loss of rotational degrees of 
freedom of the rotatable bonds in the side chain when bound to DNA.  The free energy of the 
anthraquinone system is thereby reduced as the side chain increases in length resulting in a high-
er energetic cost.  Agbandje et al. have also noted a decrease in binding affinity with increases in 
the number of methylene units in the anthraquinone side chain, as determined by molecular 
modeling 
79
.  This decrease in binding affinity was attributed to a decrease in stacking interac-
tions at the intercalation sites for the monosubstituted anthraquinones. They postulated that the 
short chain reduces the rotational degrees of freedom of the side arm which could otherwise be 
maneuvered to eliminate unfavorable steric hindrances.   
The binding of a series of anthraquinone amides with one or two peptide chains at posi-
tions 1 and/or 4  to DNA have also been investigated 
71
.  These peptidyl anthraquinones main-
tained their ability to intercalate, but somewhat changed their orientation within the base pair 
pocket compared to the parent compounds.  1,4-Anthraquinones with glycine substituent(s) in 
their side chain showed similar DNA binding affinity to that of other 1,4-disubstituted 
anthraquinones studied previously, e.g., ametantrone (3.4 x 10
5 
M
-1
) .  Replacing a glycine with a 
L-lysine in the anthraquinone side chain increased the binding affinity to 18.5 x 10
5 
M
-1
 while the 
D-isomer was even more effective with a binding constant of 33.0 x 10
5 
M
-1
.  The D-isomer had 
two times the affinity of the L-isomer to DNA duplex and about fourteen times that of di-glycine 
10 
substituent.  The increased basicity of the side chain due to the presence of the lysine results in 
favorable interaction with the phosphodiester backbone.  A higher binding constant was thus ob-
served. 
Construction of an anthraquinone-cisplatin complex has been synthesized to investigate 
the cooperative binding effect of cisplatin and anthraquinone with dsDNA 
72-73
.  The 
anthraquinones studied were linked to the cisplatin complex at various positions as either a 
monodentate ligand or a bidentate ligand.  The monodentate anthraquinone complex showed 
similar activity (ED50 of 45 µM) to the free ligand against P388 leukemic cells.  The bidentate 
ligands (3-C and 6-C alkyl chain between the anthraquinone and platinum complex) substituted 
in position 2 of the anthraquinone showed activity 10-fold less than the free ligand.  The 
bidentate ligands substituted at position 1 of the anthraquinone exhibited higher activity than the 
free ligand.  Complexes with a 3-C alkyl spacer showed an almost 100-fold greater activity com-
pared to its analog which is substituted in position 2.  Both bidentate complexes with 6-C alkyl 
linker were not very active.  In general, cisplatin-anthraquinone complexes substituted at position 
1 had a higher binding constant (10
6 
M
-1
) than complexes substituted at position 2 (10
4 
M
-1
).    
The affinities of anthraquinone, cyclam-anthraquinone and, copper-cyclam-
anthraquinone for duplex DNA have been studied
74
.  As indicated by UV spectrophotometric 
titrations, addition of a macrocycle increased the binding of anthraquinone to DNA, Ka of 4.7 x 
10
3
 M
-1
 and addition of copper to this complex further increased its affinity Ka of 6.2 x 10
3 
M
-1
.  
The binding constant for the Cu complex was ~3 times greater than that of the Zn complex 
which had a binding constant of 2.8 x 10
4
 M
-1
.   
Zinc complexes of anthraquinone have also been investigated due to their ability to act as 
a Lewis acid and hence perhaps play a role in the hydrolytic cleavage of DNA
75
.  The com-
11 
pounds showed highest activity when the alkyl spacer between the zinc unit and the 
anthraquinone unit was largest, that is C8.  Up to a 15-fold increase in cleavage for the conjugat-
ed metal complexes was observed when compared to the metal-triaminocyclohexane complex 
alone.  These results were confirmed by molecular mechanics calculations where it was seen that 
after intercalation of the anthraquinone, the alkyl side chain folds in a manner to position the zinc 
complex close to the phosphate backbone and promote cleavage.  Alkyl chains that are shorter 
resulted in less interaction of the metal with the phosphate group. 
Ihmels and Otto have given an overview of anthraquinone modifications including those 
substituted with amine-containing side groups, those with DNA cross-linking potential, those 
that generate free radicals upon intercalation, and those in combination with transition metal 
complexes 
31
. 
1.4.1 Kinetic Studies on Threading Anthraquinones 
Threading intercalators represent a class of high affinity DNA binding agents that interact 
by inserting the chromophore between the DNA bases and locating one substituent into each 
groove 
22, 85-90
.  One substituent of the intercalator binds in the major groove and the other sub-
stituent interacts with the minor groove.  Several representative threading intercalators can be 
seen in Figure 3; these include the 2,7-disubstituted anthraquinones, 9,10-disubstituted 
anthracenes, and the napthalene bis(carboximide).   
Perhaps the first threading intercalator to be studied kinetically was nogalamycin, with an 
anthraquinone core flanked by two bulky sugar moieties 
91-93
 .  The two bulky sugar substituents 
on opposite sides of nogalamycin requires that one of the sugar groups thread through the 
stacked nucleobases of the double helix to bind via threading intercalation 
94
.  Crystal structure 
of nogalamycin bound to the 5’ cytosine methylated duplex, d(CGTACG)2, shows the neutral 
12 
nogalose sugar and the methyl ester residing in the minor groove and the positively charged bi-
cyclic amino sugar residing in the major groove stabilized by hydrogen bonds to the CG base 
pair 
94
.  The reaction kinetics of nogalamycin with ct-DNA is complex, requiring at least three 
exponentials to fit 
93
.  Threading of nogalamycin is thought to involve an initial threading inter-
calated state followed by reorganization, and shuffling to a more favored thermodynamic binding 
site.  Nogalamycin has a slow rate of dissociation from DNA(kd = ~ 10
-3
 s
-1
) 
91
.   
Daunomycin is also an anthraquinone-based structure.  Although it is best viewed as a 
classical intercalator, the kinetics of intercalation have similarities to those of nogalamycin.  It 
has dissociation rates >1.0 s
-1
 
95
.  Detailed kinetic analysis showed  three relaxation processes 
95
.  
The kinetic data was interpreted as a model which involved a rapid bimolecular association step 
followed by two sequential isomerization steps.  This is believed to correspond to a rapid “out-
side” binding of daunomycin to DNA, followed by intercalation of the drug, then either confor-
mational adjustment of the drug or DNA binding site or redistribution of bound drug to preferred 
sites.   
The kinetics of smaller, less complex, anthraquinone structures have also been evaluated.  
Tanious et al. have studied the kinetics of 1,4-, 1,8-, 1,5-, and 2,6-anthraquinone derivatives sub-
stituted with amino alkyl side chains 
70
. Association and dissociation rates for the threading 
mode were shown to be approximately 10 times lower than the classical modes.  The kinetic data 
required two exponentials to fit with rate constants for both phases ≤ 6.  The two closely related 
intercalated complexes were believed to perhaps represent binding to two classes of binding site 
or from either groove of the DNA.  One of the goals of the current study is to extend our under-
standing of the threading intercalation mechanism. 
13 
1.4.2 Energetics of Anthraquinone Binding to DNA 
The free energy, ∆G, of intercalation may be obtained from the experimentally deter-
mined binding constants.  Parsing the free energy of binding of a ligand to DNA is of interest in 
several groups 
96-102
.  Chaires have parsed the binding free energy of an anthraquinone-related 
intercalator into five additive terms 
103
 which are described below.  
  ΔGobs = ΔGconf + ΔGhyd + ΔGt+r + ΔGpe + ΔGmol           Equation 1.1 
where ΔGconf is free energy contribution from conformational changes in the ligand and DNA, 
ΔGhyd is the free energy of hydrophobic transfer of a molecule from solution to its binding site, 
ΔGt+r is the free energy loss from translational and rotational motion upon complex formation, 
ΔGpe is the polyelectrolyte contribution to the binding free energy, and ΔGmol is the free energy 
arising from molecular interactions with the ligand and DNA.   
For formation of the intercalation complex, the DNA undergoes significant conforma-
tional changes.  The helix has to unwind and lengthen to separate adjacent base-pair to create an 
intercalation site.  These structural changes in the DNA are energetically unfavorable and repre-
sent an endergonic contribution to ΔGobs.  Several attempts to estimate the magnitude of this con-
tribution have been made 
50
; however, ΔGconf is generally accepted to be ~4 kcal mol
–1
, as deter-
mined by detailed kinetic studies by Macgregor et al 
104
.  The kinetic mechanism for the binding 
of ethidium to DNA was determined, and showed an obligatory DNA conformational transition, 
interpreted as opening of the helix prior to ethidium intercalation.  The corresponding equilibri-
um constant yielded a free energy cost of ~ 4 kcal mol
–1
.  Benight et al. have shown that the un-
stacking free energy of DNA is sequence dependent and therefore, postulated that the sequence 
selectivities of particular intercalators may be governed by conformational changes in the DNA 
105
.  In contrast, there has been little evidence to suggest that the intercalator undergoes signifi-
14 
cant conformational change.  As such, formation of the intercalation site is the primary contribu-
tor to ΔGconf 
50
. 
The largest favorable free energy contribution comes from the hydrophobic effect, ΔGhyd 
50
.   Intercalators have aromatic ring systems that are intrinsically hydrophobic in nature; transfer 
of these rings from a hydrophilic solution to the hydrophobic binding site of the DNA is energet-
ically favorable.  Estimates from hydrophobic transfer energies may be obtained from changes in 
the heat capacity upon intercalation, [ΔGhyd ~ 80 (±10)×ΔCp] 
106.  ΔGhyd can also be estimated 
from the change in the solvent accessible surface area (SASA) upon complex formation, ΔGhyd ~ 
-22(±5)×ΔSASA 106-108.   The hydrophobic contribution to the overall binding free energy of 
daunomycin to DNA was estimated to be ΔGhyd ~ –13 kcalmol
–1 50
. 
ΔGt+r is the free energy cost resulting from losses in translational and rotational degrees 
of freedom upon complex formation.  When a bimolecular complex is formed, three rotational 
and three translational degrees of freedom for each reactant are replaced by a single set for the 
complex.  This results in a significant loss of entropy, corresponding to an unfavorable free ener-
gy contribution; however, some of this energetic loss is compensated for by six internal vibra-
tional modes 
109
.  The magnitude of the loss of translational and rotational entropy is still under 
debate, because of the difficulty of obtaining experimental data along these lines.  Spolar and 
Record have empirically derived a value for the free energy of translational and rotational free-
dom, from the consideration of the thermodynamics of specific cases that appeared to represent 
rigid body association 
110
.  An average value of 14.9 (±3.0) kcal mol
-1
 was obtained for ΔGr+t. 
The polyelectrolyte contribution to the binding free energy, ΔGpe, arises from the release 
of condensed counterions from DNA upon complex formation.  The free energy of polyelectro-
lyte contribution is given by the equation  
15 
ΔGpe = ZφRT(mψ) ln [M
+
]     Equation 1.2 
where Z is the charge on the ligand, φ is the fraction of monovalent cation associated per DNA 
phosphate, and M
+
 is the monovalent salt concentration.  Zφ can be derived from the equation 
derived by Record and coworkers 
111
: 
-Zφ = (δ ln K/δ ln M+)     Equation 1.3 
in which K is the ligand binding constant.  The magnitude of ΔGpe depends on the charge of the 
ligand.  The polyelectrolyte contribution, ΔGpe, to the overall free energy, ΔGobs, 
 
of daunomycin 
binding to DNA is approximately -1 kcalmol
-1 50
.  The majority of this contribution is due to the 
release of condensed counter ions from the DNA upon binding.  Uncharged intercalators also 
have a favorable polyelectrolyte contribution, since the lengthening of the DNA upon complex 
formation leads to a decrease of its charge density along the backbone and subsequently to a re-
lease of counter ions 
112-113
.  Overall, the polyelectrolyte contribution for an intercalator with a 
+1 charge will range from 0 to -4 kcalmol
-1 114
. 
The free energy of molecular interactions, ΔGmol, in a complex is usually difficult to 
quantify 
50
.  It has contributions from noncovalent bonding interactions such as hydrogen bond-
ing, π-stacking, and Lewis acid–base interactions.  Few data for ΔGmol of intercalation complex-
es are known.  The most efficient approach to determine ΔGmol is through structure-activity rela-
tionship by varying the substitution pattern of a known intercalator and then conducting detailed 
binding studies 
50
.  The results will give a structure-property correlation that allows the determi-
nation of ΔGmol.  One such example is that of daunomycin and doxorubicin, which differ by a 
single OH group at position 9.  Removal of the 9-OH group from doxorubicin (to form 
daunomycin) resulted in a 1.1 kcal mol
-1
 loss in binding free energy, a magnitude that is con-
sistent with estimates of the energy for formation of a single hydrogen bond 
115
.  This is con-
16 
sistent with X-ray crystal structure which shows the 9-OH substituent of doxorubicin forms a 
hydrogen bond with the central guanine within the drug binding site 
62
.    
1.5 Research Goals 
The objective of this research project is to understand the effect of side chain length on 
the binding interactions and mechanism of anthraquinones intercalators with AT-rich, GC-rich, 
and CT- DNA.   
To achieve this goal, three homologous series of anthraquinone intercalators, (classical 
and threading) were synthesized.  An array of biophysical techniques, ultraviolet-visible (UV-
VIS), circular dichroism (CD), biosensor-surface plasmon resonance (SPR), isothermal titration 
calorimetry (ITC), fluorescence, stopped-flow, and molecular dynamics (MD) simulations were 
utilized.  The mode of binding, affinities, thermodynamics, kinetics, and molecular dynamics 
with various DNA sequences are discussed.  This dissertation is divided into five chapters which 
are described below: 
Chapter 1, the current chapter, gives a general introduction to targeting DNA with small 
molecules as an effective strategy for drug design.   
Chapter 2 is divided into two sections: The first section is a direct copy of our work for 
publication: Jackson Beckford, S., Dixon, D.W.  Synthesis and Biophysical Characterization of 
the Binding of a Homologous Series of Anthraquinone Intercalators with DNA, (intended publi-
cation to Biochemistry).  This section presents the synthesis and characterization of the binding 
interactions of a homologous series of classical anthraquinone intercalators with DNA.  The 
binding interactions with both AT- and GC-rich DNA were characterized using CD, SPR, and 
ITC.  The SPR experiments were performed by Dr. Yang Liu, and analyzed by SJB.  All other 
experiments were performed and analyzed by SJB.   
17 
The second section presents additional experimental data which will not be reported in 
the publication.  These include additional NMR, CD, SPR and ITC data used in our analysis of 
the data presented in the first section. 
Chapter 3 describes the synthesis and thermodynamic analysis of a homologous series of 
dicationic anthraquinone amides. 
Chapter 4 is a direct copy of our published work: Jackson Beckford, S., Dixon, D.W. 
(2012) Molecular Dynamics of Anthraquinone DNA Intercalators with Polyethylene Glycol Side 
Chains.  JBSD 29(5): 1065-1080.  This article describes a detailed molecular dynamic simulation 
of the homologous series of intercalators discussed in Chapter 2 with GC-rich DNA. 
Chapter 5 discusses kinetic studies of both threading and classical intercalators. 
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Figure 1.1: Structures of minor groove binding ligands 
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2 EFFECT OF SIDE CHAIN LENGTH ON DNA BINDING AFFINITY  
2.1 Work to be published 
Synthesis and characterization of a homologous series of anthraquinone intercalators 
binding to DNA 
2.1.1 Abstract  
The synthesis of four homologous anthraquinones (AQ I-IV) bearing increasing lengths 
of polyethylene glycol (PEG) side chains and their binding to AT- and GC-rich DNA hairpins 
are reported.  The molecules were designed such that the cationic charge is at a constant position 
and the ethylene glycol units chosen to allow significant increases in chain length with minimal 
changes in hydrophobicity.  The mode and affinity of binding were assessed using circular 
dichroism (CD), nuclear magnetic resonance (NMR), surface plasmon resonance (SPR), and iso-
thermal titration calorimetry (ITC).  The binding affinity decreased as the AQ chain length in-
creased along the series with both AT- and GC-rich DNA.  ITC measurements showed that the 
thermodynamic parameters of AQ I-IV binding to DNA exhibited significant enthalpy-entropy 
compensation.  The enthalpy became more favorable while the entropy became less favorable.  
Changes in the enthalpic term along the series partly reflect interactions of the PEG side chain 
with DNA; a decrease in the conformational freedom of the side chains upon binding contributes 
to the entropic term. The correlation between enthalpy and entropy may involve not only the side 
chains, but also changes in the binding of water and associated counterions and hydrogen bond-
ing.  The importance of entropic considerations is also seen in the observation that DNA binding 
of intercalators shows more dependence on the number of rotatable bonds in the side chain than 
on the hydrophobicity of the ligand. 
28 
2.1.2 Introduction 
The design of small molecules that target duplex DNA sequences is an area of continued 
interest in chemistry, biology and medicine.
1-5
  A major goal is to design molecules, both 
intercalators and groove binders, which target DNA with greater specificity and increased bind-
ing affinity.  Characterization of ligand-DNA complexes with X-ray crystallography
6-8
 and NMR 
spectroscopy
9-14
 has led to fairly detailed understanding of the structural factors involved in 
DNA binding.  Structural data, however, need to be accompanied by thermodynamic
15-18
 and ki-
netic
19-22
 studies to elucidate the driving forces for binding interactions and for a complete under-
standing of the effects of substituent changes on binding affinity and specificity. 
Intercalators that interact with DNA can be thought of in terms of the aromatic core and 
the appended side chains.  The designs of their side chains may result in important differences in 
their DNA-binding behaviors.  Modifications to the intercalators’ side chains have been impli-
cated in altering the solubility of the molecule,
23-24
 creating additional interactions that enhance 
DNA binding affinity and specificity,
25-29
 changing the kinetics of interactions,
30-31
 and their bio-
logical activities.
32-34
 
The anthraquinone-related molecules have many applications as biologically relevant 
chromophores, including in chemotherapy
35
 and studies of electron transfer in DNA.
36-40
  The 
introduction of an amide substituent into the anthraquinone (AQ) ring system allows elaboration 
of the system through the attachment of various side chains.  In this context, the position and/or 
nature of the side chain on the AQ amides with the nitrogen bound in the 2-position, has been 
shown to affect its DNA binding mode,
41-42
 binding affinity,
42-43
 specificity,
42
 recognition of dif-
ferent DNA structures,
44
 extent to which it stabilizes DNA,
45-47
 cytotoxicity,
43, 48-49
 and DNA 
29 
cleavage.
50-52
  The direction of the amide bond is known to modulate DNA recognition and inhi-
bition.
53
   
In the present study, we have systematically increased the side chain length of 
anthraquinone DNA intercalators to reveal fundamental contributions of the side chain in terms 
of the ligand’s affinity for DNA and the entropy and enthalpy of binding.  For the side chains, we 
have used increasing lengths of polyethylene glycol (PEG).  PEG, a neutral molecule, is used as 
an osmolyte in studies with DNA due to its minimal interaction with DNA, water solubility, lack 
of toxicity, stability, commercial availability, and varying molecular weights.
54-61
  A PEG side 
chain allows for a significant increase in chain length with minimal changes in hydrophobicity.
62
  
The cationic charge has been maintained at a constant position in the series to facilitate direct 
comparison, since it is known that that the position of the cation can affect the binding character-
istics of AQ.
63
   
A previous study in our group involved a homologous series of AQ derivatives with two 
symmetrical side chains on opposite side of the central core.  Those derivatives bound to DNA 
via a threading mechanism;
64
 a decrease in DNA binding affinity with an increase in side chain 
length was observed.  The current series involves derivatives with a single side chain (AQ I-IV, 
Figure 1).  Both surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) 
have been used to assess the thermodynamic effects of molecular size on DNA binding affinity.  
For these derivatives, the binding constant also decreased as the PEG side chain increased in 
length, with an increase in favorable enthalpy and decrease in entropy (more negative TΔS) 
along the series.  Molecular dynamics (MD) simulations have provided an important 
complement to the thermodynamic data in defining the molecular forces that drive binding.
65
   
30 
For a ligand binding to DNA, the enthalpic and entropic contributions dictate the Gibbs 
free energy and thus the ligand’s binding affinity.  The enthalpy is associated with two main con-
tributors: non-covalent interactions between the ligand and DNA and rearrangement of water 
molecules upon ligand interaction with DNA.
66
  The entropy is also associated with two main 
contributors upon complexation: release or uptake of water molecules and counterions and con-
formational restriction of the ligand when bound to DNA.
66
  Tighter binding affinities can be 
achieved by favorable changes in either the enthalpic term or the entropic term, or both.  Howev-
er, enthalpy-entropy compensations are frequently evident and a favorable enthalpy is often 
compensated by an unfavorable entropy.
67-69
  The homologous series used allow a close look at 
the effect of defined changes in the side chains on both the enthalpy and entropy of binding. 
For both of our series, as well as other homologous intercalators binding to DNA,
64-65, 70-
74
 there seems to be a strong dependence of the binding affinity on the side chain length rather 
than the hydrophobicity of the molecule.  In our series, this effect was only partly due to the ef-
fect of DNA in restricting the space available to the side chains.  A significant enthalpy-entropy 
compensation of the binding of ligands to DNA indicates that the situation is complex, involving 
not only the ligand and DNA, but presumably also water and counterions.  
2.1.3 Materials and Methods 
2.1.3.1 Synthesis of AQ I, N-(3-[(3-methoxy-propylamino]-propionylamino]-9,10-dioxo-9,10-
dihydro-anthracen-2-yl)-propionamide.   
Following the procedure from Agbandje et al.,
43
 a mixture of 3-bromopropionyl chloride 
(5.0 mL, 50 mmol) and 2-aminoanthraquinone (1.0 g, 4.5 mmol) was heated at 85 
o
C for 2 h.  
The mixture was allowed to cool to room temperature, filtered and the product washed with di-
ethyl ether to afford 3-bromo-N-(9,10-dihydro-anthracen-2-yl)-propionamide (1.2 g, 3.4 mmol) 
31 
as a yellow green powder.
43, 52
  This product (1.2 g, 3.4 mmol), potassium carbonate (2.9 g, 21 
mmol) and methoxypropylamine (1.9 g, 21 mmol) were refluxed in absolute ethanol (30 mL) for 
4 h.  The product was filtered and the filtrate evaporated under reduced pressure.  The 
anthraquinone amide was partially purified by silica gel chromatography eluting with 
CH2Cl2/MeOH, 1:1.  The amide was further purified by HPLC on a Shimadzu LC-10AT VP sys-
tem and a Zobax C18 reverse phase column.  Elution conditions: CH3CN-MeOH (flow rate = 1.5 
mL/min), 0-10 min (CH3CN 0%-100%), 10-35 min (CH3CN 100%-50%) to yield a yellow solid 
(37 mg, 0.10 mmol, 2.9%).  
1
H NMR (400 MHz, CDCl3) δ 11.65 (br s, 1H), 8.27 (m, 4H), 8.12 
(s, 1H), 7.89 (m, 2H), 3.57 (t, J = 6.3, 2H), 3.38 (s, 3H), 3.04 (t, J = 5.6, 2H), 2.88 (t, J = 6.3, 
2H), 2.57 (t, J = 5.6, 2H), 2.18 (br s, 1H), 1.92 (quintet, J = 6.3, 2H); 
13
C NMR δ 182.5, 181.8, 
171.9, 144.5, 134.7, 134.5, 134.3, 129.0, 128.8, 127.5, 124.9, 116.4, 71.1, 58.6, 46.3, 45.0, 35.2, 
29.8 (
1
H and 
13
C NMR spectra are in Supplemetal Material). HRMS (ESI) calcd for C21H23N2O4 
[M]
+
: 367.1658, found: 367.1671. 
2.1.3.2 Synthesis of AQ II, N-(3-[3-{2-methoxy-ethoxy}-propylamino]-propionylamino}-9,10-
dioxo-9, 10-dihydro-anthracen-2-yl)-propionamide.  
Following the procedure for the synthesis of AQ I, 3-bromo-N-(9,10-dihydro-anthracen-
2-yl)-propionamide (1.5 g, 4.2 mmol), potassium carbonate (2.9 g, 12 mmol) and 3-(2-
methoxyethoxy)propylamine (2.8 g, 21 mmol) were refluxed in absolute ethanol (30 mL) for 4 h.  
After purification, AQ II was obtained as a yellow solid (49 mg, 0.12 mmol, 2.9%). 
1
H NMR 
(400 MHz, CDCl3) δ 11.63 (br s, 1H), 8.48 (s, 1H), 8.10 (m, 4H), 7.68 (m, 2H), 3.60 (t, J = 5.9, 
2H), 3.49 (m, 4H), 3.36 (s, 3H), 3.04 (t, J = 5.8, 2H), 2.87 (t, J = 5.9, 2H), 2.58 (t, J = 5.8, 2H), 
1.94 (quintet, J = 5.9, 2H); 
13
C NMR δ 182.5, 181.7, 171.8, 144.7, 134.6, 134.4, 134.3, 129.2, 
128.8, 127.5, 124.8, 116.8, 71.7, 70.1, 70.0, 59.0, 46.9, 45.1, 35.5, 29.8 (
1
H and 
13
C NMR 
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spectra are in Supplemetal Material).  HRMS (ESI) calcd for C23H27N2O5 [M]
+
: 411.1920, found: 
411.1900. 
2.1.3.3 Synthesis of AQ III, N-(3-[3-{2-methoxyethoxy-ethoxy-propylamino]-propionylamino}-
9,10-dioxo-9,10-dihydro-anthracen-2-yl)-propionamide.  
Following the procedure from Brustolin et al. 
75
 for Michael addition, a catalytic amount 
of sodium methoxide (0.6 g) was added to a well-stirred solution of di(ethylene gycol) methyl 
ether (28 g, 0.23 mol) in acrylonitrile (25 g, 0.46 mol); the mixture was stirred for 2 h at 0 
o
C.  
Three drops of concentrated hydrochloric acid were added and the unreacted acrylonitrile evapo-
rated in vacuo. After addition of chloroform, the insoluble side products were filtered and the 
product concentrated under vacuum to give 3-[2-(2-methoxyethoxy)ethoxy]propionitrile (15 g, 
0.091 moles).
76
  Under 60 psi H2 pressure, the nitrile (2.9 g, 0.017 mol) in 2 M ethanolic ammo-
nia (40 mL) was catalytically hydrogenated in the presence of Raney-nickel in water (2 g) using 
a Parr apparatus.  When no more H2 was consumed, the reaction mixture was filtered over Celite 
and the filtrate evaporated in vacuo yielding 3-[2-(2-methoxyethoxy)ethoxy]propylamine (2.3 g, 
0.013 moles).
76
 
 The amine (13 mmol) was allowed to react with 3-bromo-N-(9,10-dihydro-
anthracen-2-yl)-propionamide (4.2 mmol) in potassium carbonate (2.1 g, 15 mmol) under reflux 
in absolute ethanol (30 mL) for 4 h.  The product was filtered and the filtrate evaporated under 
reduced pressure.  The anthraquinone amide was partially purified by silica gel chromatography 
eluting with CH2Cl2/MeOH, 1:1.  The amide was further purified by HPLC and the product ob-
tained as yellow solid (77 mg, 0.17 mmol, 4.0%). 
1
H NMR (400 MHz, CDCl3) δ 11.60 (br s, 
1H), 8.28 (m, 4H), 8.12 (s, 1H), 7.77 (m, 2H), 3.67 (m, 8H), 3.63 (t, J = 6.1, 2H), 3.38 (s, 3H), 
3.03 (t, J = 5.7, 2H), 2.88 (t, J = 6.1, 2H), 2.56 (t, J = 5.7, 2H), 1.93 (quintet, J = 6.1, 2H), 
13
C 
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NMR δ 182.4, 181.7, 171.7, 144.6, 134.8, 134.7, 134.5, 129.2, 128.8, 127.4, 124.8, 116.9, 71.7, 
70.1, 69.9, 58.8, 46.7, 45.0, 35.5, 29.7 (
1
H and 
13
C NMR spectra are in Supplemetal Material).  
HRMS (ESI) calcd for C25H31N2O6 [M]
+
: 455.2182, found: 455.2173. 
2.1.3.4 Synthesis of AQ IV, N-(3-[2-{2-(2-methoxy-ethoxy)-ethoxy-ethoxy-propylamine}-
propionylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-yl)-propionamide.  
Tri(ethylene glycol) monomethyl ether (24 g, 0.14 mol) was reacted as described above 
(synthesis of AQ III) and purified by HPLC to give AQ IV as a yellow solid (50 mg, 0.10 mmol, 
2.4%). 
1
H NMR (400 MHz, CDCl3) δ 11.55 (br s, 1H), 8.34 (m, 4H), 8.29 (s, 1H), 7.81 (m, 2H), 
3.66 (m, 12H), 3.54 (m, 2H), 3.37 (s, 3H), 3.05 (t, J = 5.2, 2H), 2.90 (t, J = 6.2, 2H), 2.58 (t, J = 
5.2, 2H), 1.92 (quintet, J = 6.2, 2H), 
13
C NMR δ 182.5, 181.7, 172.0, 144.9, 134.8, 134.6, 134.4, 
129.0, 128.8, 127.4, 124.9, 116.9, 71.8, 71.7, 70.3, 70.1, 69.9, 59.2, 46.8, 45.1, 35.5, 29.9 (
1
H 
and 
13
C NMR spectra are in Supplemetal Material).  HRMS (ESI) calcd for C27H35N2O7 [M]
+
: 
499.2444, found: 499.2465. 
2.1.3.5 Determination of Binding Mode using NMR 
NMR spectra were obtained on a Varian Unity plus 500 MHz spectrometer.  DNA sam-
ples (150 µM) were dissolved in 0.5 mL of phosphate buffer, (10 mM NaH2PO4, 10 µM EDTA, 
100 mM NaCl, pH 7.0), dried under N2 gas and finally dissolved in 90% H20 - 10% D2O.  An 
initial temperature study was conducted from 25 
o
C to 5 
o
C on the NMR spectrophotometer.  All 
imino protons were seen at 5 
o
C.  Titrations of AQ II with both AT- and GC-rich DNA hairpins 
were conducted over a range of AQ-DNA ratios from 0.5 to 10 under slow exchange conditions 
(5 
o
C).  The complete sequences are 5'-biotin-CGCGCGCGTTTTCGCGCGCG and 5'-biotin-
CATATATATCCCCATATATATG where the hairpin loops are underlined.  The GC base pair 
was placed at the end of the AT-rich hairpin to minimize fraying.  The Jump-Return pulse se-
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quence was used for water suppression.  The NMR experiments were obtained with a spectral 
width of 5000 Hz, ~ 16,000 data points, a relaxation delay time of 1.5 s, and 2 Hz line broaden-
ing.  Data were processed by MestReNova 5.0.3 software.   
2.1.3.6  Determination of Binding Mode using Circular Dichroism 
CD spectra were obtained on a Jasco J-710 spectrometer (software supplied by Jasco) in a 
1 cm cell in the range 200-650 nm.  A buffer baseline scan was initially collected and subse-
quently subtracted from the average scan for each CD experiment.  The hairpin concentration in 
all cases refers to the strand concentration, which is also the duplex concentration.  DNA hairpin 
samples, 10 µM were incubated with AQ II at various ratios (ri = 0, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 
6.0, 7.0, 8.0) at 25 
o
C in MES10 buffer (1.0 mM EDTA, 0.1 M NaCl and 10 mM MES, pH 6.24) 
for 5 min at room temperature before each spectral analysis.  Measurements were collected at 50 
nm/min using a 0.5 nm step and a response time of 0.5 s.  Five scans were accumulated and au-
tomatically averaged.  Data manipulation and plotting was done using the program Kaleidagraph 
version 4.0.  To obtain the binding constant of anthraquinone to DNA, the data for GC-rich hair-
pin with AQ II were fitted to the following interaction model for nonlinear least-squares optimi-
zation of the binding parameters: 
 
Ei = E0 + (Ef – E0) * √(Lt + Dt + Kd)-((Lt + Dt + Kd)
2
 – 4DtLt) / 2[Dt]               eq 1 
 
where Ei is the ellipticity at a given concentration, i throughout the titration, E0 is the ini-
tial ellipticity of DNA, Ef is the ellipticity of the fully formed DNA-complex, Lt is the total ligand 
concentration added at time i, Dt is the total DNA concentration used and, Kd is the dissociation 
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constant.  Ef was fitted to -4 mdeg which was close to the ellipticity obtained at the end of the 
titration, -5 mdeg at 250 nm.    
Binding interaction with AT-rich DNA did not fit the one-binding site model, instead, it 
required a two binding site interaction model.  A two binding site model requires four complex 
variables for fitting;
77
 variable correlation can be a significant issue with this many parameters.  
A binding curve was therefore calculated from the SPR K1 and K2 using equation 2 below:
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Ei = Ei[DNA] + Ei[AQ-DNA] + Ei[AQ2-DNA]    eq 2 
 
where [AQ-DNA] is the concentration of the DNA-complex after the first AQ ligand is bound 
and [AQ2-DNA] is the concentration of the DNA-complex after the second ligand is bound.  This 
equation is expanded to give equation 3 to solve for the predicted Ei: 
 
Ei = EDNA + EAQ-DNAK1[AQ] + EAQ2-DNAK1K2[AQ]
2
[DNA]t/(1+K1[AQ]+K1K2[AQ]
2
) eq 3 
 
The ellipticity values for AQ-DNA and AQ2-DNA were assumed to be -3 and -4, respectively. 
2.1.3.7 Surface Plasmon Resonance (SPR).   
SPR analysis was conducted using a four-channel BIACORE 3000 system (BIAcore, 
Inc.) to measure real-time interactions between DNA coupled to a streptavidin coated sensor chip 
(SA) and anthraquinones under constant flow.  The anthraquinone solutions were prepared in 
sterile filtered and degassed MES buffers: 10 mM MES, (pH 6.4), 0.1 mM EDTA, 0.1 M NaCl 
and 0.005% surfactant P20 by serial dilutions from stock solution.  Anthraquinone concentra-
tions varied from 10 nM - 14 µM; a Cary 50 Bio UV-Visible spectrophotometer was used to 
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measure the concentration of the stock, the molar absorptivity assumed to be 9,800 mol
-1
dm
3
cm
-
1
.
 64
  The sensor chip was conditioned with three consecutive 1-min injections of 1 M NaCl in 50 
mM NaOH followed by extensive washing with HBS-EP buffer (10 mM HEPES, 0.15 M NaCl, 
3 mM EDTA, 0.005% surfactant P20, pH 7.4); surfactant P20 was purchased from Biacore.  Two 
flow cells were used to immobilize the 5'-biotinylated DNA hairpins in HBS-EP buffer to the 
sensor chip via biotin capture while the third was left blank as a control.  A flow rate of 2 µL/min 
was used to control the amount of DNA bound; approximately 350 RU of DNA was captured in 
each case.  The experiments were carried out in MES10 buffer and samples injected at a flow 
rate of 20 μL/min. Interaction analysis was performed by steady-state methods with multiple in-
jections of different compound concentrations at 25 ºC.  The compounds were dissociated and 
the surface regenerated using the running buffer and regeneration buffer (10 mM Gly, pH 2).  
The baseline was then reestablished, and the next sample injected.  The SPR data was evaluated 
using the BIAevaluation software and the binding constants determined using Kaleidagraph (ver-
sion 3.5, Synergy Software, PA, USA). 
The reference response from the blank cell was subtracted from the response in each cell 
containing DNA to give a signal (RU, response units) that is directly proportional to the amount 
of bound compound.  The predicted maximum response per bound compound in the steady-state 
region (RUmax.pred.) was determined from the DNA molecular weight (MWDNA), the response of 
the DNA itself on the flow cell (RUDNA), the compound molecular weight (MWcompound) and the 
refractive index gradient ratio of the compound and DNA (RI).  For this series of compound, RI 
was taken to be 1.2.
79
  
 
RUmax. pred. = (RUDNA x MWcompound x RI)/MWDNA     eq 4 
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To obtain the affinity constants, the data were fitted to a one- or two binding site interac-
tion model using Kaleidagraph as shown below: 
 
RU = RUpred * (K1Cfree + 2K1K2Cfree
2
) / (1 + K1Cfree + K1K2Cfree
2
)   eq 5 
 
where K1 and K2 are macroscopic equilibrium constants for two binding sites (for a single site 
model, K2 is zero).  Cfree is the concentration of free compound (and remains constant during the 
experiment due to continuous flow of the compound). 
The observed RU values for AQ binding to the GC-rich hairpin were about 3 times lower 
than that observed for the AT-rich hairpin.  However, the AQ ligands binding to the GC-rich 
hairpin required one binding constant while binding to the AT-rich hairpin required two binding 
constants.  The reason for this irregularity was due to the GC-rich hairpin requiring a larger con-
centration of the AQ-ligand for saturation, due to its lower binding constants.  We however used 
similar AQ-concentrations for both AT- and GC-rich experiments for two reasons.  Firstly, using 
higher AQ concentrations was avoided to prevent problems such as excessive dimerization or 
adhering to the container surface.  Secondly, both AT- and GC-rich hairpins were placed on the 
same chip for direct comparison of results.  The data was sufficient to fit to a one-site binding 
model.  A calculated plot using the Ka obtained from SPR, RUpred and the concentrations used 
gave similar RUobs values. 
2.1.3.8 Isothermal Titration Calorimetry (ITC) 
ITC experiments were carried at 25 
o
C using a VP-ITC microtitration calorimeter 
(Microcal, Inc., Northhampton, MA).  ITC experiments were conducted by injecting 3 µL of the 
38 
0.3 mM anthraquinone solution in MES10 buffer every 300 s for a total of 98 injections into a 
0.01 mM AT or GC-rich DNA hairpin solution in the same buffer.  Integration of the area under 
each peak of the titration plot as a function of time gave the heat produced for each injection.  
Control experiments to determine the heats of dilution for the DNA and each AQ-ligand were 
carried out by injecting MES buffer solution into DNA or ligand into buffer alone.  The dilution 
heat for the DNA was negligible and constant and was therefore subtracted from the interaction 
heats of ligand into DNA titration.  The corrected binding isotherm for ligand binding to DNA 
was fit to an appropriate binding model with Origin 7.0, using equilibrium binding constants ob-
tained from SPR to determine the binding parameter ∆Hobserved.   
The heat of dilution titration profile for each ligand was typical for a molecule that self-
associates.  The dilution isotherm was therefore fit to a dimer dissociation model (Microcal 
Origin 7.0 software) as described in the equation below.
80-81
 
 
qi = ∆Hdiss [AQ2]syr dVi - ∆Hdiss ([AQ2]i - [AQ2]i-1) * (Vo + dVi/2)   eq 6 
 
where qi is the heat change with each successive addition of AQ, ∆Hdiss is the heat of dissociation 
of the dimer, [AQ2]syr, [AQ2]i and [AQ2]i-1 are the dimer concentrations in the syringe, after the 
i
th
 and (i-1)
th
 injection, respectively, dVi  is the volume of concentrated solution injected into the 
calorimeter cell of constant volume Vo.  The (Vo + dVi/2) term is an effective volume which 
takes into account the displacement which occurs in a total filled cell. 
The determined ∆Hdissociation value was subtracted from the ∆Hobserved value to give a cor-
rected value for the binding-induced enthalpy change.  The change in entropy, ∆S, was calculat-
ed from ∆G = ∆Hbinding - T∆S. 
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2.1.4 Results  
2.1.4.1 Determination of Binding Mode (NMR and Circular Dichroism).  
Although anthraquinones are usually intercalators, in some instances they have been 
shown to interact with the DNA also as groove binders.
63, 82-83
  Therefore, we began by evaluat-
ing the binding mode using NMR and circular dichroism (CD).  One-dimensional spectra of ex-
changeable protons were acquired at 5 
o
C to 25 
o
C in 5 
o
C increments.  The imino signals were 
most well resolved at 5 
o
C, so all other NMR experiments were conducted at this temperature.  
Titration of the AT-rich hairpin with AQ II to a stoichiometry of 1:10, Figure 2, showed pertur-
bation of the imino resonances.  The spectrum integrated for the nine imino resonances of the 
AT-rich hairpin.  Over the course of the titration, most resonances appeared to have shifted up-
field by 0.1 ppm or greater compared to the free DNA.  Similarly, eight imino resonances were 
seen for the GC-rich hairpin and about half the signals appeared to have shifted upfield at the end 
of the titration (data not shown).  An upfield shift in DNA imino resonances is indicative of in-
tercalation.
84
   
 Circular dichroism experiments were performed to study the DNA binding prop-
erties of the AQ ligands, which do not exhibit any optical activity in the absence of DNA.  Figure 
3 shows the CD spectra of AQ II titrated with the AT-rich DNA hairpin.  The uncomplexed AT-
rich hairpin exhibited a negative band at approximately 244 nm due to base stacking and a posi-
tive band at about 280 nm due to the hairpin’s helicity, typical of B-DNA.85  Significant 
hypochromicity was seen for both bands over the course of the titration.  In addition, the positive 
band showed a bathochromicity of about 10 nm. 
The CD spectra in the GC-rich hairpin titration were qualitatively similar to that of the 
AT-rich DNA titration.  The GC-rich DNA hairpin complex exhibited significant 
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hypochromicity at wavelengths 250 and 280 nm, Figure 4.  A bathochromic shift of about 12 nm 
was also observed for the positive band.  However, the AT- and GC-rich hairpin spectra were 
quantitatively distinct from each other, with a higher concentration of AQ II required for satura-
tion of the GC-rich hairpin.   
The circular dichroic effect arising from binding of AQ II to both AT- and GC-rich DNA 
hairpins allowed for an estimation of the binding constant.  Figure 4 (bottom) shows the change 
in ellipticity at 250 nm as a function of the concentration of AQ II for the GC-rich hairpin.  The 
data was fitted to a one-binding site model to obtain a binding constant of 1.4 ± 0.2 x 10
4
 M
-1
.    
In contrast, the binding data for AT-rich DNA hairpin did not fit to a one binding site model.  
However, the molar ellipticity at 244 nm as a function of AQ II concentration was consistent 
with a curve generated from the SPR binding constants (vide infra) for this system (Figure 3, 
bottom). 
2.1.4.2 SPR Analysis to Determine the Binding Affinity.  
To investigate the binding interactions of AQ I-IV with AT- and GC- rich DNA, SPR 
was used.  SPR can provide useful information on the binding affinity and stoichiometry of DNA 
interactions.  Representative sensograms for the binding of AQ I to AT- and GC-rich hairpins 
are shown in Figure 5; sensograms for AQ II-IV can be found in the Supporting Information.  
The SPR showed fast association and dissociation kinetics in the concentration range studied.  
RU values at steady state were used to generate binding plots as a function of ligand concentra-
tion.   
Table I lists the binding constants of compounds AQ I-IV for both AT- and GC-rich 
DNA hairpins.  The binding of AQ I-IV with the AT-rich DNA had a 2:1 stoichiometry for all 
compounds studied.  The equilibrium constants for binding of the first ligand, K1, were two to 
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four times higher than binding of the second ligand, K2.  Binding constants for the primary bind-
ing site decreased from 11.3 x 10
4
 – 7.2 x 104 M-1 as the length of the side chain increased.  The 
equilibrium binding constants obtained for binding of the second ligand, K2, did not show a pat-
tern in going from AQ I-IV. 
 In contrast to the AT-rich hairpin, the best fit for the binding to the GC-hairpin 
required one binding constant, consistent with the results obtained from CD.  AQ I-IV showed a 
somewhat weaker affinity for binding GC-rich hairpin in comparison to the AT-rich hairpin; 
however, the trend was very similar.  Equilibrium binding constants decreased over the range 4.1 
– 1.8 x 104 M-1 as the length of the side chain increased (Table I).  The anthraquinone with the 
shortest side chain (AQ I) bound approximately two times more tightly in comparison to that 
with the longest side chain. 
2.1.4.3 Isothermal Titration Calorimetry.  
ITC experiments were performed with both the AT- and GC-rich DNA hairpins to obtain 
a full thermodynamic profile of the interactions of AQ I-IV.  Figure 6 shows ITC profiles of the 
binding to the AT-rich hairpin.  The upper panels in the figures represent the raw ITC curves re-
sulting from the injection of AQ I-IV into the DNA hairpin solution.  The data were corrected 
separately for the heats of dilution of the DNA and the ligand.  The heat of dilution of the DNA 
was found to be constant and very small.  This was subtracted from the raw calorimetric data.  
Plots of the corrected heat released versus the AQ-DNA molar ratio are shown in the lower pan-
els of Figure 6.   
The heats of dilution for the AQ ligands were not constant, which is typical for a ligand 
undergoing dissociation.  A review of the literature showed that anthraquinones can form dimers 
in solution.
46, 86-88
  A closely related anthraquinone amide has been shown to have a dissociation 
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constant of 3.1 x 10
-4
 M.
46
  In our work, the dilution curves were fitted to the dimer dissociation 
model described in the experimental using the literature dissociation constant. 
The heat of dissociation of the dimers for AQ I-IV was 1.0 ± 0.1 kcal/mol.  This value 
was used in each case to correct the observed enthalpy of interaction of AQ ligands with DNA: 
 
ΔHobserved = ΔHdissociation + ΔHbinding    eq 7 
 
Equation 7 assumes that the ligand is fully dissociated in the calorimeter cell.  This was a 
reasonable approximation in these experiments, with more than 90% of the AQ in its monomeric 
form even at the highest concentration of AQ used.   
The data for AQ I-IV binding to the AT-rich DNA was fitted to a two site binding model 
using the K1 and K2 values obtained from SPR.  For the first ligand, binding enthalpies with the 
AT-rich DNA hairpin became more favorable as the length of the AQ side chain increased, rang-
ing from -7.08 kcal/mol to -13.6 kcal/mol (Table I).  The entropy values, on the other hand, be-
came more unfavorable as the chain length increased (T∆S = 0.15 to -7.20 kcal/mol).  The fitted 
∆H2 and calculated T∆S2 for the second (weaker) binding site for each complex showed no pat-
tern as a function of side chain length.  In addition, some compounds had relatively high values 
for both ∆H and T∆S, presumably resulting from the low binding constant (SPR) and possible 
correlation of data.  ΔH values, therefore, are reported only for the first binding process in Table 
I. 
Binding parameters for AQ I-IV with GC-rich DNA are also shown in Table I (figures 
are in the Supporting Information).  The SPR data fitted well to a single binding constant, given 
as K1 in the Table.  The ITC experiments were better fitted by a two-site sequential binding 
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model.  In this fitting, K1 was assigned to the value determined by SPR while the K2 and ∆H pa-
rameters were allowed to float.  The second binding constant (~10
3
 M
-1
) was taken as weak, non-
specific binding to the GC-rich DNA hairpin, perhaps due to the high ratios of ligand to DNA 
used in the ITC titrations (ratios of up to 5 AQ:1 DNA).  For the first (primary) binding site in 
the GC hairpin, as the AQ side chain increased in length, the enthalpy became more favorable, 
from -4.95 kcal/mol to -11.7 kcal/mol, and the entropy became more unfavorable, from 1.24 
kcal/mol to -5.98 kcal/mol.  This pattern was very similar to that observed for binding to the AT-
rich hairpin.  However, binding enthalpies for the GC-rich hairpin were generally about 2-3 
kcal/mol less favorable and binding entropies about 1-2.5 kcal/mol more favorable than for the 
AT-rich hairpin. 
2.1.5 Discussion  
2.1.5.1 Spectral Evidence Showing AQ Intercalation in DNA.   
The changes in the chemical shifts and line widths of the imino protons of DNA when 
bound to a ligand are indicative of its binding mode.
84
  Intercalation leads to line-broadened sig-
nals and upfield chemical shifts of the imino protons due to the ring currents exerted by the aro-
matic chromophore.  In contrast, groove binding induces small downfield shifts of the resonanc-
es.  The anthraquinone-based intercalators nogalamycin,
89
 daunomycin,
84
 sabarubicin,
90
 doxoru-
bicin derivatives,
91
 and an anthraquinone sulfonamide 
63
 have been studied by NMR techniques.  
Binding of these anthraquinone intercalators to DNA caused an upfield shift of the imino reso-
nances.  In our work, binding of anthraquinone to both AT- and GC-rich DNA resulted in an up-
field shift of the imino protons, indicative of intercalation.   
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2.1.5.2 Conformational Changes in DNA Monitored by Circular Dichroism.  
The conformational changes in the DNA upon binding to the AQ ligands were monitored 
by circular dichroism.  The CD spectrum of B-form DNA exhibits a positive band at about 280 
nm due to base stacking and a negative band at about 250 nm due to the helicity of the DNA.
92
  
Upon AQ binding, both the AT- and GC-rich hairpins showed significant hypochromicity for 
both the 280 and 250 nm bands and bathochromicity of the peak at 280 nm.  Intercalators are 
known to unwind the DNA helix to allow the DNA base pairs to separate for binding.  The 
changes seen in the DNA CD signals signify alterations in both the DNA base stacking and 
helicity upon AQ binding, observed also for the anthraquinone intercalators nogalamycin and 
daunomycin.
93-94
  
An induced signal for the AQ bound to either AT- or GC-rich DNA was not seen.  
Breslin et al. have made a similar observation with an anthraquinone sulfonamide.
63
  They found 
that at low concentrations of the AQ-DNA complex (similar to ours), the induced CD ligand sig-
nal was too weak to be measurable.  In general, groove binders exhibit much stronger induced 
CD signal intensity than do intercalated compounds.
95-96
 
2.1.5.3 Binding Affinity.  
Binding constants determined by SPR indicated moderate ligand-DNA affinities with 
values of Ka ~10
4 
M
-1
.  Association constants of 10
4
 - 10
5
 M
-1
 have been previously determined 
for the binding of other AQ amides to DNA.
42-43, 46, 52, 63, 82, 97-100
  The AQ ligands in our study 
had a moderate preference for AT-rich DNA, binding approximately three-fold more tightly than 
with GC-rich DNA (Table I).  Other anthraquinone amides showing AT-selectivity have been 
reported.
63-64, 98
  Preferential intercalator binding at AT-sites may be due to specific hydrogen-
bonding interactions between the side chain atoms and the AT base pairs.
101
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2.1.5.4 Thermodynamic Characterization of AQ I-IV Binding to DNA.   
Binding of AQ I-IV to the primary binding sites of both AT- and GC-rich DNA was 
enthalpically driven.  Calculations showed that the favorable enthalpies of binding had contribu-
tions from electrostatic interactions between the side chain ammonium group and phosphate 
groups, a hydrogen bond between the side chain amide and DNA, and water bridges between the 
AQ chromophore and DNA.
65
   
The binding enthalpy became more negative along the series AQ I-IV, decreasing from   
-7.08 to -13.6 kcal/mol for AT-rich DNA and -4.95 to -11.7 kcal/mol for the CG-rich DNA.  Mo-
lecular dynamics (MD) simulations showed that the PEG side chain was more localized in the 
groove as the side chain became longer.
65
  PEG is a neutral molecule widely used as an osmolyte 
in DNA studies; it is generally viewed as having minimal interaction with the DNA. The MD 
results, however, suggest interactions between the side chain and the DNA, presumably due to 
the forced high local concentration of the PEG in the DNA groove.  This is expected to contrib-
ute favorably to the enthalpy. 
The MD simulations also showed release of water molecules hydrogen bonded to the 
PEG side chain.  This effect increased with the length of the side chain, with approximately 10% 
(AQ I) to 25% (AQ IV) of the side chain PEG-bound water molecules released upon ligand 
binding to the DNA.  For AQ IV there was a high correlation between conformations with the 
side chains localized in the DNA groove and a decrease in the number of internal water bridges 
in the side chain, presumably due to the formation of favorable side chain-DNA interactions for 
this structure. The water molecules released from the side chain ether oxygens form hydrogen 
bonds with bulk water.  The change in hydrogen bonding of these water molecules from a water-
ether linkage to a water-water linkage presumably results in a net strengthening of hydrogen 
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bonding, thus contributing favorably to the enthalpy.  Lu et al. showed that water molecules tend 
to cluster with increasing concentration of 1,2-dimethoxyethane solution,
102
 which may be indic-
ative of the stronger hydrogen bonds formed between water molecules. 
The entropic component of the free energy became more unfavorable as the length of the 
side chain increased.  TΔS decreased from 0.15 to -7.20 kcal/mol along the AT series and 1.24 to 
-5.98 kcal/mol along the GC series.  MD simulations showed the motions of the AQ side chains, 
when bound to DNA, were inhibited by the groove wall and therefore could only sample space 
away from the AQ chromophore.  This effect became more significant as the side chain length-
ened.  Increased localization of the PEG side chain in the DNA groove also contributed unfavor-
ably to the binding entropy by further restricting the motions of the side chain.  
MD simulations comparing the free and bound AQ, showed a net change in T∆Sconf of 3.4 
kcal/mol for the complexes with the GC hairpin.   This compares with a net change found in the 
experiments for T∆S of 7.22 kcal/mol.  Thus, the T∆S range in the experiments is approximately 
twice that in the MD simulation.  This is presumably because the entropy derived from MD sim-
ulation only accounted for the range of motions of the side chain, but not for other controlling 
aspects such as entropy due to loss or gain in water and/or counter ions during binding of the lig-
and to DNA. 
The change in entropy may also be influenced by the release of water molecules from the 
side chain.  If the released water molecules undergo strengthening of hydrogen bonds due a 
change from water-ether to water-water interactions, the change in entropy could be unfavorably 
affected (discussed in more detail below).  Higher density water regions appeared to decrease as 
the side chain increased in length.  Overall, the free energy of conformational change for 
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intercalators bearing a long or flexible side chains can contribute significantly to the free energy 
of binding of a ligand to DNA and ultimately, its binding affinity. 
2.1.5.5 Enthalpy-Entropy Compensation.  
The magnitude of the changes over the series in the enthalpies (∆H > 6 kcal/mol) and en-
tropies (T∆S > 3 kcal/mol) for binding were not reflected in the change in the free energy of 
binding; the change in ∆G was < 1 kcal/mol from AQ I to AQ IV.  Enthalpy-entropy compensa-
tion has been observed in previous studies of DNA binding.  Figure 7 shows an enthalpy-entropy 
compensation plot of data obtained from binding of the AQ ligands studied herein as well as data 
obtained from the literature (compiled by J.B. Chaires). 
69
  The data chosen by Chaires were se-
lected on the basis that enthalpy values were calorimetrically determined, binding free energies 
were determined from independently measured binding constants, and the data were acquired 
under solution conditions of 25 °C, pH 7, 0.2 M NaCl.  Our data met the first two criteria and 
solution conditions were similar to those in the previous compilation (25 °C, pH 6.4, 0.15 M 
NaCl).   
Groove binders and intercalators fall along different parts of the correlation, with the 
former having more unfavorable enthalpies and more favorable entropies than the latter.  Our 
data set falls along the line of other mono-intercalators, extending the series in the data for AQ 
III and AQ IV.  Bis-intercalators (the two points in the lower right of the graph, Figure 7)
103-104
 
show much more favorable enthalpies and unfavorable entropies, as might be expected for the 
binding of two moieties to the DNA.  The enthalpy-entropy correlation is seen over a large num-
ber of different structures of DNA binding molecules and appears independent of even the mode 
of binding (groove binding or intercalation).  In our series, the compensation increases smoothly 
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in the order AQ I < AQ II < AQ III < AQ IV.  Thus, the longer side chains result in a higher 
compensation.   
Enthalpy-entropy compensation has been previously observed in a variety of processes 
involving nucleic acids, including melting of single strands, hairpins and duplexes,
105-109
 nucleic 
acid folding,
110
 and the interactions of nucleic acids with ligands.
67-69, 111
  For the examples in 
Figure 7, the interactions of groove binders are entropically driven and those of intercalators are 
enthalpically driven.  The reasons for the enthalpy-entropy correlations are unclear, but may in-
volve changes in the binding of water and associated counterions, hydrogen bonding, and the 
collective dynamics of the ligand-DNA complex.   
The role of water may be significant in enthalpy-entropy compensations in ligand-DNA 
interactions.
67
  Ligands that bind to the minor groove of DNA have been shown to effect the re-
lease of water from the groove e.g., Hoechst 33258,
112
 DAPI,
113
 the benzimidazole derivatives 
DB183 and DB185,
114
 and netropsin.
115
  The release of water molecules from the groove binder-
DNA complex would be expected to result in favorable entropy.  In contrast, intercalator binding 
is often accompanied by water uptake; e.g., for propidium, proflavine, daunomycin, and 7-
aminoactinomycin D.
116
  This results in more negative entropies of complex formation.  In addi-
tion, the formation of new hydrogen bonds between water and the DNA complex could result in 
a more favorable enthalpic term. 
The role of water can also be viewed in terms of hydrogen bonds formed and broken.
111
  
In this model, release or uptake of water molecules is viewed primarily as a redistribution of hy-
drogen bonds.  Work by Pimentel et al. on model systems has indicated that hydrogen bond for-
mation (favorable enthalpy) is accompanied by an unfavorable entropy,
117
 presumably due to a 
loss in molecular motion.  The observed enthalpy-entropy compensation could therefore arise 
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from the release of waters from the side chain to form hydrogen-bonds with bulk water mole-
cules.  The increase in enthalpy due to formation of hydrogen-bonds is compensated by the loss 
in molecular motions of the water molecules.    
A third aspect of enthalpy-entropy compensation is the restriction of molecular motion 
due to intermolecular forces including hydrophobic interactions, hydrogen bonds and electrostat-
ic interactions.  Searle and Williams have postulated the compensating effect of these non-
covalent interactions in nucleic acid melting studies.
105
  Dunitz has used a statistical mechanical 
model to derive a semi-quantitative estimate for enthalpic and entropic components when two 
molecules interact.
118
  This model suggests that an increase in enthalpic contributions from non-
covalent interactions of the ligand and DNA is accompanied by a restriction of the motions of the 
ligand and DNA, resulting in a decrease in entropy.  Whatever the mixture of physical effects 
that underlie enthalpy-entropy compensation, it is clear that this phenomenon is seen for a varie-
ty of different molecules binding to DNA as both groove binders and intercalators. 
2.1.5.6 Effect of Increasing Side Chain Length on DNA Binding Affinity..  
Our data may be compared with other quantitative studies of homologous intercalators 
binding to DNA.  Most homologous series are created with addition of methylene units to the 
side chain(s).  Maleev and co-workers looked at the binding of actinocin derivatives with CT-
DNA.
72
  Wakelin et al. 
70
 and Atwell et al. 
71
 measured binding of similar homologous series of 
aminoacridine and acridines, respectively, to both AT-and GC-rich DNA.  Zhang et al. studied 
two sets of acenaptho[1,2-b] pyrrole derivatives.
73
  Ovchinikov et al. investigated the binding of 
actinomycin homologs.
74
  In all five of these series, the extension of the side chains by meth-
ylene units resulted in structures that became more hydrophobic as the side chains became long-
er.  There are two studies of homologous series in which the side chains are increased by –
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CH2CH2O– groups, the current study and previous work in this laboratory on threading 
intercalators by McKnight et al.
64
  For both of these series, the structures became more hydro-
philic and the binding constant decreased as the side chains became longer.  All of the data are 
plotted in Figure 8a.  Overall, there is no dependence of the binding constant on hydrophobicity 
(expressed as XlogP of the molecule
62
).   
In all the seven series studied, however, there is a decrease in binding constant as the 
number of rotatable bonds in the side chain increases; the data are plotted in Figure 8b.  This 
change in binding constant is independent of increasing or decreasing hydrophobicity, one or two 
side chains, threading or “classical” modes of binding, and mono- or dicationic structures.  This 
significant correlation of binding constant in each series with the number of rotatable bonds indi-
cates the importance of the side chain in controlling the DNA binding constant.  However, con-
trol is only partly due to the effect of DNA in restricting the space available to the side chains.  
The significant enthalpy-entropy compensation of the binding of ligands to DNA indicates that 
the situation is complex, involving not only the ligand and DNA, but also water and counterions. 
2.1.6 Conclusions.  
This study has reported the binding of four homologous anthraquinones (AQ) bearing 
PEG-based side chains to both AT- and GC-rich hairpins.  The binding affinity and thermody-
namic parameters were assessed via SPR and ITC measurements.  The AT-rich sequence bound 
two AQ while the GC-rich sequence bound one AQ ligand.  The binding affinity decreased 
slightly as the AQ chain length increased along the series AQ I-IV with both AT- and GC-rich 
DNA.  Conversion of the binding constants to binding free energy showed small changes in ∆∆G 
of less than 1 kcal/mol along the series; this small change arose from enthalpy-entropy compen-
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sation, that is, the enthalpic term became more favorable and the entropic term became less fa-
vorable along the series.   
Changes in the enthalpic term along the series probably reflect increased interactions of 
the side chain with DNA as the chain length increases.  This is consistent with related molecular 
dynamics studies on this system that show increasing localization of the PEG chain in the groove 
as it becomes longer.  PEG is generally viewed as having minimal interaction with DNA; our 
work indicates that PEG does interact with the DNA, presumably due to the forced high local 
concentration in the DNA groove.  The enthalpic term may also be affected by the rearrangement 
of water molecules upon AQ-DNA interaction.  The water molecules released from the side 
chain can form hydrogen bonds with bulk water; the hydrogen bonds involving water are strong-
er than those with the ether linkage, resulting in a net increase in favorable enthalpy.   
Changes in the entropic term are thought to arise from two main factors.  First, upon 
binding to DNA, the conformational freedom of the PEG side chains is restricted by the DNA.  
Ligands bearing longer side chains are expected to pay a higher entropic cost because the side 
chains can no longer sample space above and below the chromophore.  Second, formation of hy-
drogen-bonds by the release or uptake of water molecules by the AQ-DNA complex restricts the 
molecular motions of water molecules, which also contributes unfavorably to the entropy. 
Binding of intercalators to DNA can be parsed in terms of a series of free energy contri-
butions, including ΔGconf, the free energy contribution from conformational changes in the DNA 
and ligand upon binding.  Conformational changes for intercalators binding to DNA are often 
neglected, both because many intercalators do not have significant numbers of rotatable bonds, 
and because T∆S for many is small.  This study shows that there is an entropic cost when 
intercalators with long side chains bind to DNA.  This is greater the longer the side chain and is 
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significant enough to cause a decrease in DNA binding affinity.  The importance of entropic con-
siderations is also seen in the observation that DNA binding of intercalators shows more depend-
ence on the number of rotatable bonds in the side chain than on the hydrophobicity of the ligand. 
More generally, not only this series of DNA binding molecules but many others show 
significant enthalpy-entropy compensation.  Enthalpy-entropy compensation is a complex phe-
nomenon, involving not only noncovalent interactions between the ligand and DNA, but also re-
arrangement of the water molecules involved in the complex with the resulting changes in hy-
drogen bonding.   
2.2 Unpublished Work.  
2.2.1 NMR: Determination of the Binding Mode of AQ to GC-rich DNA.  
Titration of the GC-rich hairpin with AQ II to a stoichiometry of 1:10, Figure 2.9, 
showed perturbation of the imino resonances.  The spectrum integrated for the eight imino reso-
nances of the GC-rich hairpin.  Over the course of titration, about half the resonances appeared to 
have shifted upfield by 0.1 ppm or greater compared to the free DNA.  An upfield shift in DNA 
imino resonances is indicative of intercalation.
84
   
2.2.2 CD: Derivation of the Binding Constant of AQ II binding to DNA 
The binding affinities of small molecules binding to DNA can be estimated from non-
linear curve fitting of the CD binding isotherm at specific wavelengths using various software 
programs, such as Kaleidagraph.  Derivation of the binding constant for systems of 1:1 binding 
stoichiometry has been previously reported,
78
 and is shown in equations 2.1-2.9.  The binding of 
AQ II to GC-rich hairpin was fitted to a 1:1 binding stoichiometry.  Binding interaction of AQ II 
with AT-rich DNA did not fit the one-binding site model.  Binding models with two interaction 
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sites or greater requires four or more complex variables for fitting; 
78
 variable correlation can be 
a significant issue with this many parameters.  A binding curve was therefore calculated from the 
SPR K1 and K2 using the derivation described in equations 2.10-2.19 below.
78
 
2.2.2.1 Derivation of one-site binding isotherm.  
The AQ ligand, L is assumed to bind reversibly to the DNA macromolecule, M to form 
ML with a dissociation constant, Kd.  The total concentrations of M and L are denoted Mt and Lt, 
respectively, and the ellipticity of M and ML is given by E.  The drug has no ellipticity.  From 
the equilibrium condition and mass conservation, the following is obtained: 
M + L               ML 
Kd = [M][L]/[ML]         (2.1) 
Mt = [M] + [ML]         (2.2) 
Lt  = [L]  + [ML]         (2.3) 
Substitute equations 2.2 and 2.3 into 2.1, it follows that 
Kd = [Mt – ML][Lt – ML]/[ML]       (2.4) 
[ML]Kd = [Mt][Lt] – [ML][Lt] – [ML][Mt] + [ML]
2
 or    (2.5) 
[ML]
2
 - (Lt + Mt + Kd) – (Lt + Mt) = 0      (2.6) 
which is expressed as  
ML = √(Lt + Mt + Kd)-((Lt + Mt + Kd)
2
 – 4MtLt)/2       (2.7) 
Since, 
[ML]/[Mt] = (Ei – E0) / (Ef – E0),        (2.8) 
where E0 is ellipticity of free macromolecule, Ef  is the ellipticity when all the macromolecule is 
fully bound and Ei is the ellipticity at any given concentration of ligand, then, ML is given as  
Ei =  E0 + (Ef – E0) * √(Lt + Mt + Kd)-((Lt + Mt + Kd)
2
 – 4MtLt)/2 [Mt]   (2.9) 
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2.2.2.2 Derivation of two-site binding isotherm.  
The derivation of the 1:2 binding starts with two equilibrium binding constant expression 
(2.10 and 2.11) and two mass balance equations (2.12 and 2.13) obtained from two equilibrium 
equations.  The AQ ligand, L is assumed to bind reversibly to macromolecule, M to form ML 
with association constant K1.  A second ligand L then binds to ML with an association constant, 
K2.  The total concentrations of M and L are denoted Mt and Lt, respectively, and the combined 
ellipticity of M, ML, and ML2 is given by E.  From the equilibrium condition and mass conserva-
tion, the following is obtained: 
M + L             ML 
 ML + L             ML2 
K1 = [ML]/([M][L])         (2.10) 
K2 = [ML2]/([ML][L])         (2.11) 
Mt = [M] + [ML] + [ML2]        (2.12) 
Lt  = [L]  + [ML] + 2[ML2]        (2.13) 
Substituting equations 2.10 and 2.11 into 2.12, it follows that 
[M] = [Mt]/1+K1[L] + K1K2[L]
2 
       (2.14) 
[ML] = K1[L][Mt]/1+K1[G] + K1K2[L]
2 
      (2.15) 
[ML2] = K1K2[L]
2
[Mt]/1+K1[G] + K1K2[L]
2 
      (2.16) 
Substituting equations 2.15 and 2.16 into equation 2.13 yields equation 2.17, in which the un-
known variables are [L], K1, and K2. 
[L]t = [L] + (K1[L] + 2K1K2[L]
2
)[Mt]/1+K1[L] + K1K2[L]
2 
    (2.17) 
Rearranging equation 2.17 results in a cubic equation for [L],   
A[L]
3
 + B[L]
3
 +C[L] + D = 0 
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where, 
 A = K1K2 
 B = K1 + 2K1K2[Mt] – K1K2[Lt] 
C = 1 + K1[Mt] – K1[Lt] 
D = - [Lt] 
The relationship of the ellipticity data to [L] and [M] is: 
Ei = EM[M] + EML[ML] + EML2[ML2]      (2.18) 
(L does not have an ellipticity value). 
Substituting equations 2.14-2.16 into equation 2.18 yields 
Ei = (EM + EMLK1[L] + EML2K1K2[L]
2
)[Mt]/1+K1[L] + K1K2[L]
2   
(2.19) 
Equation 2.19 was used to generate a binding curve for AQ II with DNA.  The ellipticity value 
for M was -21 and those for ML and ML2 were assumed to be -4 and -3, respectively.     
2.2.3 SPR: Calculated RU versus Observed RU versus Fitted RU values.  
SPR is an effective tool to measure the affinity and study the kinetics of most 
biomolecular interactions because of its high sensitivity.
119-120
  As such, SPR was used to quanti-
tatively evaluate interactions between AQ I-IV and AT- and GC-rich DNA to gain insights into 
their binding affinities.  The SPR experiments were performed with a four-channel BIAcore 
2000 optical biosensor system (BIAcore, Inc.) and streptavidin coated sensor chip as previously 
described in Section 2.1.3.7.  The instrument response (RU) in the steady state region is propor-
tional to the amount of bound drug.   
The predicted maximum response per bound compound in the steady state region 
(RUmax.pred) was determined from the DNA molecular weight (MWDNA), the amount of DNA on 
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the flow cell, the compound molecular weight (MWcompound), and the refractive index gradient 
ratio of the compound and DNA (RI).  For this series of compound, RI was taken to be 1.2.
79
  
RUmax. pred. = (RUDNA x MWcompound x RI)/MWDNA      (2.19) 
The predicted response for each AQ ligand is given in Table 2.2.  We noted that, as the 
side chain increased in length from AQ I-IV, 
a. the maximum RU values observed were increasingly lower than the RUmax.pred values 
b. the maximum RU values observed for the GC-rich series were much lower than the 
AT-rich series 
The data was refitted with RUmax.pred as an unknown variable using equation 2.2.  The fitted val-
ues obtained for RUmax.pred from non-linear least square fitting was similar to the calculated val-
ues for RUmax.pred (Table 2.2).   
The low values obtained for the maximum RU observed can be rationalized as: 
- The binding constant decreased as the AQ side chain increased in length; there-
fore, the DNA required a larger concentration along the AQ series for saturation.  Since 
similar concentrations of AQ ligands were used for titration of AQ I-IV, the DNA will be 
less saturated along the series, hence the lower RU values.   
- The binding constants for the AT-rich series were ≥ 3 that of the GC-rich se-
quence.  Therefore, the GC-rich series required a higher concentration of ligand for satu-
ration.  Since similar concentrations of ligand were used for both series, the GC-rich se-
ries displayed lower RU vales.  
2.2.4 ITC: Determination of the heats of dilution for AQ I-IV.  
Control experiments to determine the heats of dilution for the DNA and each AQ ligand 
were carried out by injecting MES buffer solution into DNA or ligand into buffer alone.  The di-
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lution heat for the DNA was small and constant and was subtracted from the heat of the AQ lig-
and binding to DNA per injection.  The corrected binding isotherm for ligand binding to DNA 
was fit to an appropriate binding model with Origin 7.0, using equilibrium binding constants ob-
tained from SPR to determine the binding parameter ∆Hobserved.   
The heat of dilution titration profile for each ligand was typical for a molecule that self-
associate.  Calorimetric dilution experiments alone cannot discriminate between dimerization 
and formation of higher order aggregates,
87
 however, Haq and coworkers have shown that simi-
lar AQ ligands are predominantly dimers 
46
.  In addition, a dimer dissociation curve is expected 
to obey a hyperbolic behavior for the dissociation of strong dimers, that is, each successive injec-
tion at the start of an ITC experiment will be expected to result in a slightly lower heat uptake 
due to the tendency of dimers not to fully dissociate even at lower monomer concentrations in 
the calorimetric cell.
121
  The heat uptake will continue to decrease slowly with further injections 
and eventually level out at zero as the concentration of monomers in the calorimetric cell reaches 
beyond the dissociation constant.  Dissociation of higher order aggregates is reported to frequent-
ly give sigmoidal dilution thermograms, in contrast to the hyperbolic shapes for the dimer disso-
ciation.  The dilution isotherm was therefore fit to a dimer dissociation model to determine 
∆Hdissociation which was subsequently subtracted from the ∆Hobserved value to give a corrected value 
for the binding-induced enthalpy change, Table 2.3. 
2.2.4.1 Derivation of the monomer-dimer equilibrium model.  
The derivation of the heat of dissociation due to dimerization is according to that present-
ed in the ITC Data Analysis Origin Tutorial Guide, Version 7.0- January 2004.  
The AQ ligand, L is assumed to bind reversibly to another AQ ligand, L to form L2 with a 
dissociation constant, Kdiss.  Injection of the L2 dimer into the calorimetric cell results in some 
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heat effects, ΔHdiss due to dissociation of the ligand as described below (taken from VP-ITC 
Manual): 
 
     L2                      2L   Kdiss = [L]
2
/[L2] 
The total concentration of ligand (given as equivalent monomer concentration) after the 
i
th
 injection, Ci, is the sum of the actual monomer concentration [L]i plus 2 times the aggregate 
concentration [L2]i.   
Ci = [L]i + 2[L2]i      (2.22) 
Using the expression for the dimer dissociation constant to obtain [L]i in terms of [L2]i 
leads to the equation: 
Ci = (Kdiss * [L2]i)
1/2
 + 2[L2]i     (2.23) 
A similar expression applies to the solution in the syringe of fixed concentration Csyr 
Csyr = (Kdiss * [L2]syr)
1/2
 + 2[L2]syr    (2.24) 
Since Csyr is known and Ci can be determined from Csyr knowing injection volumes, then 
[L2]syr and [L2]i can be determined from equations 2.23 and 2.24 if Kdiss is assigned. 
In the ITC dilution experiment, we measured the heat change qi when a small volume dVi 
of concentrated solution is injected into the calorimeter cell (constant volume V0) containing ini-
tially buffer but, for later injections, more dilute solution. The heat arises from dimers present in 
higher concentration solution that dissociate upon entering the lower concentration in the cell. 
For the i
th
 injection of volume dVi made into a fixed volume cell (V0) heat is given by: 
 qi = ∆Hdiss[L2]syrdVi - ∆Hdiss([L2]I - [L2]i-1) * (Vo + dVi/2)   (2.25) 
The (Vo + dVi/2) factor is an effective volume which takes into account the displacement 
which occurs in a total filled cell.  
 ∆Hdiss 
 
59 
In the experiments performed, we noted the dilution profile of AQ IV had an exothermic 
portion, which was not seen for the other AQ ligands.  The exothermic portion of the AQ IV di-
lution curve may be heat due to differences in the dilution of monomers and dimers that takes 
place with the injection, assumed to be constant for all injections.  Dilution of the AQ ligands 
involves hydration of the polyethylene glycol side chain.  In our MD simulations, we have 
shown that the hydration of AQ IV was significantly more hydrated in solution compared to the 
other three AQ ligands.
65
  It is therefore not surprising that the dilution titration profile for AQ 
IV was somewhat different from the other three ligands. 
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Figure 1:  Structures of the AT- and GC-rich 
DNA hairpins and 2-substituted anthraquinones 
amides, AQ I-IV, used in this study. 
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Figure 1:  Structures of the AT- and GC-rich 
DNA hairpins (hairpin loops underlined) and 2-
substituted anthraquinones amides, AQ I-IV, 
used in this study. 
AQ I 
 
AQ II 
 
AQ III 
 
AQ IV 
 
i  2.1: Anthraquinon  intercalators, AQ I-IV, used in this study.  
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Figure 2.2: Downfield region of the 
1
H NMR spec-
tra of AT-rich DNA hairpin.   
Top: Spectra as a function of temperature.  The 
peaks at 5 
o
C had the best resolution. Bottom: AQ 
II-DNA complex showing resonance of DNA imino 
protons at 5 
o
C; the AQ II-DNA ratio is given to 
the left. 
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Figure 2.3: CD spectral titration of AQ II with 10 
µM AT-rich DNA hairpin in MES10 buffer, pH 6.24 
and 25 
o
C. 
Top: CD spectra of AQ II with AT-rich DNA at var-
ious DNA:AQ II ratios (ri = 0 to 8.0).  Bottom: The 
observed ellipticity at 244 nm as a function of the 
concentration of AQ II (closed circles) and a calcu-
lated binding curve (solid line) using data from the 
SPR K1 and K2 values. 
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Figure 2.4: CD spectral titration of AQ II with 10 µM 
GC-rich DNA hairpin in MES10 buffer, pH 6.24 and 
25 
o
C. 
Top: CD spectra of AQ II with AT-rich DNA at various 
DNA:AQ II ratios (ri = 0 to 20).  Bottom: The observed 
ellipticity at 250 nm and the concentration of AQ II 
were fitted with a one-site binding model to obtain an 
equilibrium binding constant, K1 of 1.4 x 10
4 
M
-1
. 
64 
25.0
20.0
15.0
10.0
5.0
0.0 
0.0        2.0          4.0          6.0     8.0        10.0    
Concentration (µM)
R
U
30.0
25.0
20.0
15.0
10.0
5.0
0.0 
R
U
0        100       200      300      400      500      600 
Time (s)
5
10
15
20
25
0 5 10
-6
1 10
-5
1.5 10
-5
2 10
-5
2.5 10
-5
R
U
[AQ IV], M
0
2
4
6
8
10
0 5 10
-6
1 10
-5
1.5 10
-5
2 10
-5
2.5 10
-5
R
U
[AQ IV], M
10.0
8.0
6.0
4.0
2.0
0.0
0.0        2.0  4.0        6.0        8.0        10.0
Concentration (µM)
R
U
14.0
12.0
10.0
8.0
6.0
4.0
2.0
0.0
0    100      200     300     400 500     600
Time (s)
R
U
 
 
 
 
 
 
 
 
 
Figure 2.5: SPR sensograms for AQ II with AT-rich and GC-rich DNA. 
Top: SPR sensograms for AQ II with AT-rich (left) and GC-rich (right) DNA hairpin in 
MES 10 buffer, pH 6.24 at 25 
o
C.  Concentrations of AQ II ranged from 0-10 µM from 
bottom to top.  Bottom: Conversion of the SPR sensograms to a binding isotherm plot-
ting RU values from the steady-state region of the SPR sensogram versus the AQ II 
concentration.  The data were fitted to a two-site binding model for the AT-hairpin and 
a one-site binding model for the GC-hairpin using eq 5.   
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Figure 2.6: ITC curve for the binding of AT-rich DNA hairpin to a) AQ I, b) AQ II, c) 
AQ III, and d) AQ IV.   
Isothermal titrations consisted of ~95 injections (3 µL) of 300 µM AQ I-IV ligand into a 
calorimetric cell containing 10 µM of AT-rich DNA hairpin.  The top panels are plots of 
the baseline corrected experimental data.  The lower panels shows the results converted 
to molar heats and plotted against the compound to DNA molar ratio.  Experiments 
were carried out in MES 10 buffer at 25 
o
C.  The data were fitted to a two-site binding 
model.   
66 
-35
-25
-15
-5
5
15
-25 -15 -5 5 15 25
Δ
H
 (
k
c
a
l 
m
o
l-
1
)
-TΔS (kcal mol-1)  
 
 
 
 
 
 
3.0
4.0
5.0
6.0
7.0
8.0
9.0
0 10 20 30 40
L
o
g
 K
a
Rotatable Bonds
McKnight (AT)
McKnight (GC)
Maleev (0.20 M NaCl)
Maleev (0.16 M NaCl)
Wakelin (AT)
Wakelin (GC)
Jackson Beckford (AT)
Jackson Beckford (GC)
Atwell (AT)
Atwell (GC)
Zhang (CT-DNA)
Ovchinikov (CT-DNA)
3.0
4.0
5.0
6.0
7.0
8.0
9.0
0.0 2.0 4.0 6.0
L
o
g
 K
a
Xlog P  
 
Figure 2.8: Plot of the a) hydrophobicity (Xlog P) and b) rotatable bonds of various 
intercalators in the literature as a function of their binding constant.   
References are given in the text. 
 
Figure 2.7: Entropy-enthalpy compensation plot 
for drug-DNA binding data.  
The black open squares are groove binders, and 
the black open circles are intercalators from the 
literature.  The blue circles are AQ I-IV with 
AT-rich DNA and red circles are AQ I-IV with 
GC-rich DNA.  Data were taken from ref 69. 
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Figure 2.9 (S1):
 1
H NMR spectrum of AQ I in chloroform. 
68 
 
Figure 2.10 (S2): 
1
H NMR spectrum of AQ II in chloroform. 
69 
 
Figure 2.11 (S3): 
1
H NMR spectrum of AQ III in chloroform.  
 
70 
              
Figure 2.12 (S4): 
1
H NMR spectrum of AQ IV in chloroform. 
71 
               
Figure 2.13 (S5): 
13
C NMR spectrum of AQ I in chloroform. 
72 
Figure 2.14 (S6): 
13
C NMR spectrum of AQ II in chloroform. 
73 
               
Figure 2.15 (S7):
 13
C NMR spectrum of AQ III in chloroform. 
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Figure 2.16 (S8): 
13
C NMR spectrum of AQ IV in chloroform. 
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Figure 2.17 (S9): SPR sensograms for AQ I with AT-rich and GC-rich DNA. 
Top: SPR sensograms for AQ I with AT-rich (left) and GC-rich (right) DNA hairpin in 
MES 10 buffer, pH 6.24 at 20 
o
C.  Concentrations of AQ I ranged from 0 -12 µM from 
bottom to top.  Bottom: Conversion of the SPR sensograms to a binding isotherm plot-
ting RU values from the steady-state region of the SPR sensogram versus the AQ II 
concentration (bottom).  The data were fitted to a two-site binding model for the AT-
hairpin and a one-site binding model for the GC-hairpin using eq 5.   
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Figure 2.18 (S10): SPR sensograms for AQ III with AT-rich and GC-rich DNA. 
Top: SPR sensograms for AQ III with AT-rich (left) and GC-rich (right) DNA hairpin in 
MES 10 buffer, pH 6.24 at 20 
o
C.  Concentrations of AQ III ranged from 0 -14 µM from 
bottom to top.  Bottom: Conversion of the SPR sensograms to a binding isotherm plot-
ting RU values from the steady-state region of the SPR sensogram versus the AQ III 
concentration (bottom).  The data were fitted to a two-site binding model for the AT-
hairpin and a one-site binding model for the GC-hairpin using eq 5.   
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Figure 2.19 (S11): SPR sensograms for AQ IV with AT-rich and GC-rich DNA. 
Top: SPR sensograms for AQ IV with AT-rich (left) and GC-rich (right) DNA hairpin 
in MES 10 buffer, pH 6.24 at 25 
o
C.  Concentrations of AQ IV ranged from 0-12 µM 
from bottom to top.  Bottom: Conversion of the SPR sensograms to a binding isotherm 
plotting RU values from the steady-state region of the SPR sensogram versus the AQ 
IV concentration (bottom).  The data were fitted to a two-site binding model for the AT-
hairpin and a one-site binding model for the GC-hairpin using eq 5.   
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Figure 2.20 (S12): ITC curve for the binding of AT-rich DNA hairpin to a) AQ I, b) AQ 
II, c) AQ III, and d) AQ IV.   
Isothermal titrations consisted of ~95 injections (3 µL) of 300 µM AQ I-IV ligand into a 
calorimetric cell containing 10 µM of GC-rich DNA hairpin.  The top panels are plots of 
the baseline corrected experimental data.  The lower panels shows the results converted 
to molar heats and plotted against the compound to DNA molar ratio.  Experiments were 
carried out in MES 10 buffer at 25 
o
C.  The data were fitted to a two-site binding model.   
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Figure 2.21 (S13): Downfield region of the 
1
H 
NMR spectra of GC-rich DNA hairpin with AQ II.   
AQ II-DNA complex showing resonance of DNA 
imino protons at 5 
o
C; the AQ II-DNA ratio is 
shown on the left. 
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Figure 2.22 (S14): ITC curve for the dilution of 300 µM a) AQ I, b) AQ II, c) AQ III, and 
d) AQ IV in MES10 buffer.   
The top panels are plots of the baseline corrected experimental data.  The lower panels 
shows the results converted to molar heats and plotted against the equivalent monomer 
concentration of the ligand.  All ligands were diluted in MES 10 buffer and experiments 
were carried out at 20 
o
C. 
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Table 2.1: Thermodynamic data for the interaction of AQ I-IV with DNA at 25 
o
C.
*
  
Compound DNA       K1 
(10
4
  M
-1
) 
       K2 
  (10
4
  M
-1
) 
      ΔH    
(kcal/mol) 
     TΔS           
(kcal/mol) 
    ΔGobs 
(
 
kcal/mol) 
AQ I AT 11.3 ± 0.98 2.69 ± 0.50 -7.08 ± 0.34 0.15 -7.23 
 GC 4.08 ± 0.06  -4.95 ± 0.07 1.24 -6.19 
AQ II AT 8.93 ± 0.26 2.19 ± 0.19 -8.28 ± 0.33 -0.54 -7.04 
 GC 2.21 ± 0.03  -6.37 ± 0.04 0.63 -5.83 
AQ III AT 7.69 ± 0.30 1.93 ± 0.20 -11.6 ± 0.87 -4.69 -6.91 
 GC 1.94 ± 0.03  -8.23 ± 0.09 -2.48 -5.75 
AQ IV AT 7.21 ± 0.22 3.09 ± 0.14 -13.6 ± 0.47 -7.20 -6.40 
 GC 1.82 ± 0.04  -11.7 ± 0.19 -5.98 -5.72 
* 
K1 and K2 are derived from the SPR data; ΔGobs is calculated from K1.  ΔH is from ITC and  
TΔS is calculated from ΔH and ΔGobs.   
 
Table 2.2: Kaleidagraph fitting of the SPR data from the binding of AQ I-IV to AT- and GC-
rich DNA hairpins. 
Compound DNA        K1 
(10
4
  M
-1
) 
        K2 
   (10
4
  M
-1
) 
RUpred 
    
RUobs 
 
RUfit 
 
AQ I AT 11.3 ± 0.98 2.69 ± 0.50 24.3 25.5 25.8 
 GC 4.08 ± 0.06  23.4 7.90 26.4 
AQ II AT 8.93 ± 0.26 2.19 ± 0.19 27.2 24.5 25.2 
 GC 2.21 ± 0.03  26.5 8.86 30.7 
AQ III AT 7.69 ± 0.30 1.93 ± 0.20 30.2 20.6 24.5 
 GC 1.94 ± 0.03  29.3 6.34 33.5 
AQ IV AT 7.21 ± 0.22 3.09 ± 0.14 33.1 17.7 27.2 
 GC 1.82 ± 0.04  32.2 5.29 31.5 
 
Table 2.3: Results from the dilution of AQ I-IV in MES10 buffer. 
Compound Dimerization Constants  
        (10
3
 M
-1
)              
Heats of Dissociation 
          (kcal/mol)       
AQ I 5.4 0.98 
AQ II 5.9 0.97 
AQ III 4.3 1.08 
AQ IV 5.1 0.95 
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3 SYNTHESIS OF DICATIONIC ANTHRAQUINONE AMIDES  
3.1 Introduction  
In the design of drugs that bind to DNA with improved affinity, one of the major chal-
lenges is to overcome enthalpy-entropy compensation
1-2
; investigation into their structure activi-
ty relationships and thermodynamics can yield insights into the origins of their enthalpies and 
entropies
3
.  We have demonstrated, in chapter 2 that the mono-cationic anthraquinone amides, 
AQ I-IV, bind to DNA via intercalation and exhibit moderate binding affinities that decreases 
with an increase in their side chain length.  Binding of AQ I-IV to DNA is usually accompanied 
by an increasing reduction in the conformational space that their side chain can sample, which 
typically results in an entropic loss.  Formation of the AQ-DNA complex typically forms new 
interactions between the anthraquinone and its binding site, increasing as the chain length in-
creases.  However, these interactions between the ligand and DNA limit the ligand’s external ro-
tational and translational freedom (as well as ligand and DNA ﬂexibility) and, therefore, repre-
sent an entropic penalty.  The net effect of these contributions results in a decrease in binding 
affinity with an increase in anthraquinone chain length.   
In this work, we have designed and synthesized a homologous series of dicationic 
anthraquinone intercalators.  The length of the side chains was comparable to the previously syn-
thesized anthraquinone intercalators, AQD I-IV, however, bear two cationic charges.  The 
placement of the cationic charges was at either ends of the side chain.  ITC studies were con-
ducted and the results are reported in Table 1. 
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3.2 Materials and Methods  
3.2.1 Synthesis of AQD I. 
Chloroethanol (20 g, 0.25 moles) was added to a mixture of diethylamine (5.6 mL, 0.707 
g/cm
3
, 0.054 moles), potassium iodide (0.76 g, 0.0046 moles), and potassium carbonate (26.6 g, 
0.193 moles).  The mixture was refluxed for 20 h then filtered and evaporated under reduced 
pressure.  The product was washed with water, extracted with CH2Cl2, then evaporated again to 
yield 2-(diethylamino)ethanol 
4
.  Following the procedure from Brustolin et al.
5
 for Michael ad-
dition, a catalytic amount of sodium methoxide (0.35 g, 0.0065 moles) was added to a well-
stirred solution of 2-(diethylamino)ethanol (15 g, 0.13 moles) in acrylonitrile (13.6 g, 0.256 
mol).  The mixture was stirred for 2 h at 0 
o
C.  Three drops of concentrated hydrochloric acid 
were added and the unreacted acrylonitrile evaporated in vacuo. After addition of chloroform, 
the insoluble side products were filtered and the product concentrated under vacuum to give 3-
[2-(diethylamino)ethoxy]propanenitrile.
6
  Under 60 psi H2 pressure, the nitrile (0.07 mol) in 2 M 
ethanolic ammonia (40 mL) was catalytically hydrogenated in the presence of Raney-nickel in 
water (2 g) using a Parr apparatus.  When no more H2 was consumed, the reaction mixture was 
filtered over Celite and the filtrate evaporated in vacuo yielding 3-[2-
(diethylamino)ethoxy]propane-1-amine.
6
 
The amine (40 mmol) was allowed to react with 3-bromo-N-(9,10-dihydro-anthracen-2-
yl)-propionamide (8 mmol) with potassium carbonate (40 mmol) under reflux in absolute ethanol 
(30 mL) for 4 h.  The product was filtered and the filtrate evaporated under reduced pressure.  
The anthraquinone amide was purified by silica gel chromatography eluting with CH2Cl2/MeOH, 
1:1, and the product obtained as yellow solid (550 mg, 15%).  
1
H NMR (400 MHz, CDCl3) δ8.26 
(m, 4H), 8.13 (s, 1H), 7.71 (m, 2H), 3.41 (m, 6H), 2.80 (t, J = 5.6, 2H), 2.62 (t, J = 5.6, 2H), 2.49 
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(t, J = 5.8, 2H), 2.39 (q, J = 6.2, 4H), 1.63 (quintet, J = 5.6, 2H), 1.02 (t, J = 6.2, 6H); 
13
C NMR 
(400 MHz, CDCl3) δ182.1, 181.5, 171.2, 144.8, 135.2, 134.6, 133.7, 128.9, 128.7, 127.3, 124.9, 
116.6, 71.0, 65.8, 53.7, 52.6, 50.2, 45.1, 35.9, 29.8, 10.2; (
1
H NMR & 
13
C NMR spectra are in 
list of figures). 
3.2.2 Synthesis of AQD II. 
Silver oxide was prepared by addition of a solution of sodium hydroxide (6.9 g, 0.172 
mol) in water (200 mL, heated to 85 
o
C) to a solution of silver nitrate (30.0 g, 0.177 mol) in wa-
ter (200 mL) and heating to 85 
o
C.  The resulting suspension was quickly filtered, washed with 
hot water (200 mL), followed by 95% ethanol (200 mL), and then with absolute ethanol (200 
mL).  Following the procedure from Bouzide and Sauvé for monotosylation of symmetrical di-
ols,
7
 the freshly prepared silver oxide (53.6 g), p-toluenesulfonyl chloride (32 g), and potassium 
iodide (5.1 g) were added to a well stirred solution of diethylene glycol (30 g, 0.29 moles).  Fol-
lowing the procedure from Brustolin et al.
5
 for Michael addition, a catalytic amount of sodium 
methoxide (0.35 g, 0.0064 moles) was added to a well-stirred solution of the monotosylate (15 g, 
0.057 mol) in acrylonitrile (6.5 g, 0.123 mol); the mixture was stirred for 2 h at 0 
o
C.  Three 
drops of concentrated hydrochloric acid were added and the unreacted acrylonitrile evaporated in 
vacuo. After addition of chloroform, the insoluble side products were filtered and the product 
concentrated under vacuum to give the tosylated nitrile.  To a stirred suspension of the nitrile (15 
g, 0.048 mol), sodium carbonate (4.95 g, 0.048 mol), in THF, diethylamine (4.8 mL, 0.046 mol) 
was added.  The mixture was refluxed for 24 hrs then cooled and filtered.  Under 60 psi H2 pres-
sure, the nitrile (0.07 mol) in 2 M ethanolic ammonia (40 mL) was catalytically hydrogenated in 
the presence of Raney-nickel in water (2 g) using a Parr apparatus.  When no more H2 was con-
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sumed, the reaction mixture was filtered over Celite and the filtrate evaporated in vacuo yielding 
3-{2-[2-(diethylamino)ethoxy]ethoxy}propan-1-amine.
6
 
The amine (40 mmol) was allowed to react with 3-bromo-N-(9,10-dihydro-anthracen-2-
yl)-propionamide (8 mmol) in potassium carbonate (40 mmol) under reflux in absolute ethanol 
(30 mL) for 4 h.  The product was filtered and the filtrate evaporated under reduced pressure.  
The anthraquinone amide was purified by silica gel chromatography eluting with CH2Cl2/MeOH, 
1:1, and the product obtained as yellow solid (277 mg, 0.56 mmol, 7.0%). 
1
H NMR (400 MHz, 
CDCl3) δ 11.65 (br s, 1H), 8.29 (m, 4H), 8.15 (s, 1H), 7.76 (m, 2H), 3.68 (m, 8H), 3.59 (t, J = 
6.0, 2H), 3.02 (t, J = 5.6, 2H), 2.81 (t, J = 5.6, 2H), 2.63 (t, J = 5.7, 2H), 2.52 (q, J = 6.2, 4H), 
1.90 (quintet, J = 5.8, 2H), 1.04 (t, J = 6.2, 6H); 
13
C NMR (400 MHz, CDCl3) δ182.3, 181.4, 
170.4, 144.9, 135.3, 134.8, 133.9, 128.8, 128.6, 127.5, 124.9, 116.8, 73.0, 71.8, 70.5, 66.1, 52.1, 
51.6, 50.2, 45.1, 35.8, 29.8, 10.7; (
1
H NMR & 
13
C NMR spectra are in list of figures). 
3.2.3 Synthesis of AQD III. 
AQD III was synthesized using the same procedure as AQD II, except using triethylene 
glycol instead of diethylene glycol.  The anthraquinone amide was partially purified by silica gel 
chromatography eluting with CH2Cl2/MeOH, 1:1, and the product obtained as yellow solid (406 
mg, 0.75 mmol, 6.1%). 
1
H NMR (400 MHz, CDCl3) δ 11.52 (br s, 1H), 8.29 (m, 4H), 8.17 (s, 
1H), 7.75 (m, 2H), 3.61 (m, 12H), 3.54 (m, 2H), 3.01 (t, J = 5.4, 2H), 2.80 (t, J = 5.4, 2H), 2.64 
(m, 2H), 2.53 (q, J = 6.2, 4H), 1.90 (quintet, J = 5.8, 2H), 1.04 (t, J = 6.2, 6H); 
13
C NMR (400 
MHz, CDCl3) δ182.3, 181.4, 171.3, 145.1, 135.1, 134.9, 133.9, 128.7, 128.5, 127.5, 124.9, 
116.7, 72.5, 72.3, 71.8, 70.1, 66.9, 52.1, 51.5, 50.5, 45.0, 35.6, 29.9, 10.6; (
1
H NMR & 
13
C NMR 
spectra are in list of figures). 
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3.2.4 Synthesis of AQD IV. 
AQD IV was synthesized using the same procedure as AQD II, except using 
tetraethylene glycol instead of diethylene glycol.  The anthraquinone amide was partially puri-
fied by silica gel chromatography eluting with CH2Cl2/MeOH, 1:1.  The amide was further puri-
fied by HPLC on a Shimadzu LC-10AT VP system and a Zobax C18 reverse phase column.  
Elution condition: CH3CN-MeOH (flow rate = 1.5 mL/min), 0-10 min (CH3CN 0%-100%), 10-
35 min (CH3CN 100%-50%).  The product was obtained as a yellow solid (238 mg, 0.41 mmol, 
3.5%). %). 
1
H NMR (400 MHz, CDCl3) δ 8.25 (m, 4H), 8.19 (s, 1H), 7.74 (m, 2H), 3.59 (m, 
16H), 3.49 (m, 2H), 2.91 (t, J = 5.2, 2H), 2.75 (t, J = 5.2, 2H), 2.60 (m, 2H), 2.48 (q, J = 6.0, 
4H), 1.83 (quintet, J = 5.6, 2H), 1.03 (t, J = 6.0, 6H); 
13
C NMR (400 MHz, CDCl3) δ182.2, 
181.3, 171.4, 144.9, 135.0, 134.5, 133.3, 128.7, 128.5, 127.4, 124.9, 116.7, 72.8, 72.5, 71.6, 66.7, 
52.1, 51.6, 50.4, 45.1, 35.6, 29.8, 12.3; (
1
H NMR & 
13
C NMR spectra are in list of figures). 
3.2.5 Isothermal Titration Calorimetry (ITC). 
ITC experiments were carried out at 25 
o
C using a VP-ITC microtitration calorimeter 
(Microcal, Inc., Northhampton, MA).  The experiments were conducted by injecting 3 µL of a 
0.5 mM anthraquinone solution in MES10 buffer every 300 s for a total of 98 injections into a 
0.01 mM AT-rich DNA hairpin (5’-biotin-GCATATATATCCCCATATATATGC) solution in 
the same buffer.  Integration of the area under each peak of the titration plot as a function of time 
gave the heat produced for each injection.  Control experiments to determine the heats of dilution 
for the DNA into buffer were carried out by injecting MES buffer solution into DNA or ligand 
into buffer alone.  The dilution heat for the DNA was negligible and constant and was therefore 
subtracted from the interaction heats of ligand into DNA titration.  The corrected binding iso-
therm for ligand binding to DNA was fitted to a “one set of sites” binding model with Origin 7.0 
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to determine the binding parameter, equilibrium binding constant, Kobserved, number of ligands 
binding to DNA, n, and the binding enthalpy, ∆Hobserved.  The measured heat of dissociation for 
similar anthraquinone dimers was ~ 1.0 ± 0.1 kcal/mol, (see discussion in Chapter 2).  This value 
was used in each case to correct the observed enthalpy of interaction of AQ ligands with DNA: 
ΔHobserved = ΔHdissociation + ΔHbinding  
The determined ∆Hdissociation value was subtracted from the ∆Hobserved value to give a cor-
rected value for the binding-induced enthalpy change, ΔHbinding.  The change in entropy, ∆S, was 
calculated from ∆G = ∆Hbinding - T∆S. 
3.3 Results and Discussion  
The dicationic anthraquinone amides, AQD I-IV, were designed for further elucidation 
of the effect of side chain length on DNA binding affinity, as well as enthalpic and entropic 
changes as a function of changes in the ligand’s side chain.  The ITC data for AQD I-IV binding 
to the AT-rich DNA was fitted to a “one set of sites” equilibrium binding model to obtain their 
binding affinities, K, binding enthalpies, ∆H and entropies, ∆S, and the number of ligands bound 
per hairpin, n.  The equilibrium binding constants were of the order of magnitude of 5.3 x 10
4
 – 
9.1 x 10
4
 M
-1 
(Table 1), in no particular order as a function of chain length.  The equilibrium 
binding constants were similar to their mono-cationic counterparts, AQ I-IV (2.3 x 10
4
 – 1.1 x 
10
5
 M
-1
), as seen in Chapter 2.  The n values obtained, that is the number of AQD ligand bound 
per hairpin, was ≥ 4 for all four compounds.  For AQD I, ~7 ligands were bound to the hairpin, 
which is equivalent to a binding site-size of ~1.  Based on the nearest neighbor-exclusion model 
for the binding of an intercalator to DNA
8
, which states every second intercalation site along the 
DNA length remains unoccupied, a site size of ~1 is generally not expected.  For AQD I-III, the 
DNA is about half neutralized.  The AQD ligands must therefore bind non-specifically to DNA.  
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These non-standard complexes were not observed for their dicationic threading counterparts, 
AQT I-IV, which had n values of approximately two to three 
9
.  No further studies were con-
ducted on these dicationic anthraquinone ligands. 
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Figure 3.1: Anthraquinone intercalators, AQD I-IV, used in this study. 
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Figure 3.2: 
1
H NMR spectrum of AQD I in chloroform 
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Figure 3.3: 
1
H NMR spectrum of AQD II in chloroform 
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 Figure 3.4: 
1
H NMR spectrum of AQD III in chloroform 
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Figure 3.5: 
1
H NMR spectrum of AQD IV in chloroform 
102 
 
 
Figure 3.6: 
13
C NMR spectrum of AQD I in chloroform 
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Figure 3.7: 
13
C NMR spectrum of AQD II in chloroform 
1 
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Figure 3.8: 
13
C NMR spectrum of AQD III in chloroform 
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Figure 3.9: 
13
C NMR spectrum of AQD IV in chloroform 
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Table 3.1: Binding parameters of AQD I-IV as determined by isothermal titration calorimetry. 
Compound       K
(10
4
  M
-1
) 
       n 
 
     ΔH 
(kcal/mol) 
    TΔS                                 
(kcal/mol) 
ΔGobs 
(
 
kcal/mol) 
AQ I  7.70 ± 0.41 7.15 ± 0.05  -3.08 ± 0.04     -3.54    -6.62 
AQ II  8.11 ± 0.27 6.55 ± 0.03  -3.35 ± 0.03     -3.30    -6.65 
AQ III  5.32 ± 0.24 7.08 ± 0.05  -3.34 ± 0.05     -3.06    -6.40 
AQ IV  9.13 ± 0.31 4.29 ± 0.04  -2.84 ± 0.03     -3.88    -6.72 
Figure 3.10: ITC heat of dissociation curves for a) AQD I, b) AQD II, c) AQD III, and 
d) AQD IV.   
Isothermal titrations consisted of ~95 injections (3 µL) of 500 µM AQD I-IV ligand into 
a calorimetric cell containing MES10 buffer.  The data were fitted to a dimer dissocia-
tion model.   
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4 MOLECULAR DYNAMICS OF ANTHRAQUINONE DNA INTERCALATORS 
WITH POLYETHYLENE GLYCOL SIDE CHAINS  
4.1 Direct Copy of Published Work 
4.1.1 Abstract  
The interactions of a homologous series of four anthraquinone (AQ) intercalators with in-
creasing lengths of polyethylene glycol (PEG) side chains with DNA have been studied via mo-
lecular dynamics (MD) simulations.  The geometry, conformation, interactions, and hydration of 
the complexes were examined.  The geometries of the four ligands were similar with parallel 
stacking to the long axis of the adjacent DNA base pairs.  Hydrogen bonding between the AQ 
amide and DNA led to a preference for the trans-syn conformer.  As the side chain lengthened, 
binding to DNA reduced the conformational space, resulting in an increase in unfavorable entro-
py.  Increased localization of the PEG side chain in the DNA groove, indicating some interaction 
of the side chain with DNA, also contributed unfavorably to the entropy.  The changes in free 
energy of binding due to entropic considerations (-3.9 to -6.3 kcal/mol) of AQ I-IV were signifi-
cant.  The hydration of the PEG side chain decreased upon binding to DNA.  Understanding of 
side chain conformations, interactions, and hydration changes that accompany the formation of a 
ligand-DNA complex may be important in the development of new applications of pegylated 
small molecules that target biological macromolecules. 
4.1.2 Introduction  
The design of genome-directed small molecules that target specific DNA sequences and 
structures has been a recurring theme in anticancer drug development 
1-5
.  Study of the interac-
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tions of these small molecules with DNA is especially important in elucidating the specificity of 
DNA-ligand interactions and developing new and more effective drugs.  Previous studies have 
shown that interactions formed between the drug and DNA fall into two main categories: interca-
lation and groove binding 
6-12
.  Most DNA-interacting molecules possess flexible degrees of 
freedom, which give rise to a complex potential energy surface with several conformational min-
ima.  Quite frequently, even though many conformational possibilities exist in the free form, the-
se molecules adopt only one or perhaps a few preferred conformations when bound to DNA.  For 
a small rigid molecule, it may be reasonable to ignore the conformational change on binding, but 
not for more flexible ligands or those bearing long side chains.  Understanding the favorable and 
unfavorable contributions to the binding free energy of a ligand binding to DNA is important for 
the design process of drug molecules.   
Anthraquinones are an important class of molecules for cancer chemotherapy; several de-
rivatives have been successfully administered in the clinic, including daunomycin and adriamy-
cin 
13-18
.  In this context, researchers have explored the possibility of modifying the structure of 
anthraquinones to improve the overall effectiveness and decrease the toxicity of this drug class.  
The introduction of an amide substituent into the anthraquinone (AQ) ring system allows elabo-
ration of the system through the attachment of side chains.  Studies of anthraquinone amides with 
the nitrogen bound in the 2-position have included interaction with DNA structures including 
duplexes 
19-22
, triplexes 
21, 23-24
, and quadruplexes 
25-29
, as well as cleavage of the DNA in the mi-
nor groove 
30
, at abasic sites 
31
, and under irradiation 
32
.  Members of this class of molecules con-
tinue to be studied as anticancer agents 
33-38
.    
We chose to synthesize the AQ intercalators, AQ I-IV, bearing a homologous series of 
polyethylene glycol (PEG) side chains (Figure 1A) connected through an amide linkage to probe 
110 
the effect of the side chain length on DNA binding 
39
.  The PEG structure was chosen because 
the addition of each subunit is expected to have only a very small effect on the hydrophobicity of 
the molecule 
40-41
.  In addition, PEG of various lengths are widely used as osmolytes in studies of 
DNA due to their minimal interaction with DNA, water solubility, lack of toxicity, stability, 
commercial availability, and varying molecular weights 
42-49
. 
The observed free energy of binding for an intercalator, ΔGobs, has been parsed into five 
components 
50
: 
   ΔGobs = ΔGconf + ΔGhyd + ΔGt+r + ΔGpe + ΔGmol [1] 
ΔGhyd is the free energy of hydrophobic transfer of the molecule from solution to the 
DNA binding site. ΔGt+r is the free energy cost resulting from losses in translational and rota-
tional degrees of freedom upon complex formation.  ΔGpe has to do with polyelectrolyte contri-
butions resulting from the release of condensed counter ions from the DNA upon binding.  ΔGmol 
is the free energy from noncovalent molecular interactions between the molecule and DNA in-
cluding hydrogen bonds, and van der Waals, electrostatic, and dipole-dipole interactions.  ΔGconf  
is the free energy contribution from conformational changes in the DNA and ligand upon bind-
ing.  The interpretation of experimental binding studies usually assumes that conformational 
changes arising in the ligand upon binding to DNA are negligible compared to that of the DNA 
itself, and hence do not contribute significantly to the binding free energies.  Although it may be 
reasonable to ignore the conformational changes in a small rigid molecule upon binding to DNA, 
changes in conformation should be considered for more flexible ligands or those bearing long 
side chains.  In this work, AQ I-IV have PEG-based side chains of increasing length.  Because 
PEG is not expected to interact with the DNA, this is an ideal homologous series to investigate 
the effect of side chain conformational flexibility on DNA binding. 
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Molecular dynamics (MD) simulations provide an important complement to experimental 
data.  These simulations are well suited to provide insights into the conformational properties of 
a ligand, DNA or their complex.  Simulation on a sufficiently long timescale will allow for char-
acterization of the structure at the molecular level.  In this paper, we report the MD simulation of 
the AQ series when free in solution and when bound to DNA.   
There are a number of MD simulation studies that have probed the interaction, geometry, 
conformational changes, mechanism of binding, and free energies of AQ intercalators with DNA 
duplexes 
10, 51-66
.  The AQ intercalators studied include mitoxantrone, doxorubicin, daunomycin, 
and nogalamycin.  Our work extends these studies by evaluating how side chains with multiple 
degrees of freedom interact with the DNA grooves.  We compare the conformations available to 
the molecules both free in solution and when bound to a DNA hairpin. 
4.1.3 Materials and Methods  
4.1.3.1 NMR and IR of Anthraquinones, AQ I-IV  
NMR samples of AQ I 
39
 were prepared in CDCl3. Two dimensional ROESY (Rotating-
frame Overhauser Enhancement SpectroscopY) NMR spectra were recorded on a 400 MHz 
Bruker spectrometer with mixing time of 350 ms.  The ROESY data were measured with a total 
of 512 t1 increments, and 2048 data points in t2. Spectral widths of 5600 Hz were used in both 
dimensions. Data processing was carried out with the MestReNova 5.0.3 software 
67
. 
IR spectra were taken on a Perkin-Elmer 257 spectrophotometer.  The spectra of neat AQ 
ligands were obtained by co-addition of 5 scans at a resolution of 1 cm
-1
. 
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4.1.3.2 Computational Methods  
MD simulations (50 ns) were performed for the four anthraquinone ligands both free in 
solution and when bound to DNA. Starting from a model-built B-DNA hairpin 
(GCGCGCGCTTTTGCGCGCGC), the anthraquinone-DNA complexes were generated employ-
ing the AQ-DNA orientation and spacing of the anthraquinone respinomycin bound to DNA 
[1N37 in the Protein Data Bank (PDB)] 
68
.  The system was then subjected to energy minimiza-
tion on a Sybyl 8.0 (Tripos, Inc., St. Louis, MO) program by using MMFF94s force field by in-
cluding the MMFF94 partial atomic charges 
69
. 
The atomic charges of the ligand were derived by means of the RESP technique 
70
 based 
on the electrostatic potential calculated at the HF/6-31G* level using the Gaussian 03 package 
71
. 
The MD simulations were carried out using the sander module 
72
 in the Amber 9.0 suite of pro-
grams  with the modified version (ff99SB) of the parm99 all-atom force field 
73
. The starting 
structures and input files were generated using the xleap program 
73
. Both the free ligand and the 
ligand-DNA complexes were solvated in cubic periodic boxes with the TIP3P (transferable in-
termolecular potential 3P) water model 
74-75
, up to 10 Å away from the ligand or complex. For 
the free ligands and bound complex, each periodic box was filled with approximately 2700 and 
4900 water molecules, respectively.  
The starting structures were equilibrated to a pressure of 1 bar (100 kPa) and a tempera-
ture of 300 K using the ff99SB force field 
73
 implemented in the sander module with the particle 
mesh Ewald (PME) method 
76
.  Equilibration was conducted according to the following three 
steps: a minimization of 10000 steps with the first 2000 being steepest descent (to remove unfa-
vorable contacts) and the remainder being conjugate gradient.  The solvent and ions were mini-
mized while the DNA and the ligand were restrained by a 100 kcal mol
-1
 Å
-2
.  A short MD run of 
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50 ps in which the solute molecules were restrained and the water molecules allowed to relax 
was performed.  During the MD, the system was gradually heated from 0 to 300 K.  The re-
straints on the solvent and ions were applied at 50 kcal mol
-1
 Å
-2
.  For the final step of equilibra-
tion, a 100 ps MD run in which both the solute and the water molecules were allowed to relax 
was done. The final density of the system was ~ 0.989 g/mL.  
The production simulations (50 ns) were carried out with a fixed volume in which the 
temperature was maintained at 300 K. The electrostatic interactions were treated by using the 
smooth particle mesh Ewald method 
76
 with grid spacing of 0.5 Å. The cutoff distance for the 
non-bonded interactions was 9 Å. The SHAKE algorithm 
77
 was used to restrain all bonds in-
volving a hydrogen atom. Snapshots were saved every 500 steps for further analyses. To create 
all the overlaid snapshots, frames from the simulation were chosen randomly. The DNA shown 
in the overlaid snapshots is representative of the average DNA structure. 
4.1.3.3 Entropy Calculations  
The starting point of our analyses, chosen to be 10 ns, allowed the system to equilibrate 
further.  The ptraj module of the Amber 9 suite was used for analysis of the molecular trajecto-
ries and VMD for visualization.  The entropic contributions of the free AQ side chains and pen-
alties resulting from the restriction of the side chain upon binding to the hairpin duplex were de-
rived.  Ptraj calculations of configurational entropy follows the formulation by Schlitter 
78
 which 
employs a quantum mechanical harmonic oscillator ([2]).  The entropy takes into account both 
the configurational and vibrational entropy contributions arising from conformational changes in 
the ligand and addition of new modes upon binding to DNA.  The translational and rotational 
motions were eliminated by spatially superimposing the structures in the trajectory to a common 
reference structure.  This ensures eliminating the possibility of convergence problems.  The defi-
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nition for the entropy based on covariance matrix of atomic positional fluctuations of the Carte-
sian coordinates of the particles in the system is given as:  
 S = ½kB ln det [1+ kBTe
2/ħ2 Mσ]         [2] 
where kB is the Boltzmann constant, T is the temperature, e is the Euler value, ħ = h/2p; h is 
Planck’s constant, and M is the mass diagonal matrix.  The σ value is the covariance matrix of 
the atomic positional fluctuations with elements ([3]): 
           σij = <(xi − <xi>) (xj − <xj>)>                        [3] 
Schlitter’s formula is convenient when the entropy of only subgroups of atoms is of interest, in 
our case, the side chain atoms.  The application of the covariance matrix calculation was per-
formed only on the side chain heavy atoms (C, N and O) as a reduced representation of the sys-
tem, avoiding an estimate of the entropy from fluctuations of other atoms within the ligand. 
4.1.3.4 Water Occupancy  
Water distribution around the DNA was calculated using ptraj grid of the AMBER 9.0 
suite of programs.  The water distribution was calculated by binning atom positions from RMS 
coordinate fit frames over all the DNA-complex atoms at 1 ps intervals into 0.5 Å
3
 grids.  The 
value of each grid element represents the number of times the coordinates of the water oxygen 
were within the 0.5 Å
3
 represented by that particular grid element. These grids were then con-
toured using VMD 
79
.  Contouring of waters was performed at two or more times the expected 
bulk water density.  
VMD was used for analysis of the bridging water molecules. The bridging water mole-
cules in the simulations are characterized by Tcl scripts.  To capture the residence time of the 
water molecule bridging the DNA and AQ ligands or within the AQ ligand itself, the dwell time 
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distribution of waters within 3.5 Å of selected atoms was counted as described previously 
80
.  
The time distribution was then fit to an exponential to get the residence time. 
4.1.4 Results and Discussion  
Herein, we describe a systematic study of the DNA binding interactions of four AQ lig-
ands bearing increasing side chain lengths of PEG.  We first determined the conformation of the 
AQ amide in solution.  Results from IR and NMR indicated that the NH-CO (ω) bond was found 
in the trans conformation (Figure 1B).  MD simulations were used to assess the torsional behav-
ior of the NH-CO (ω) and AQ-NHCO (Φ) linkages, interactions between the AQ-ligand and 
DNA, and the conformations of the side chain.  We also evaluated the binding geometry and 
stacking interactions of the four ligands upon binding to DNA, which were similar for all the lig-
ands.  In contrast, the side chain conformations of AQ I - IV were different, as discussed below. 
4.1.4.1 Conformational Assignment of the Free AQ-amide in Solution  
The amide link in our AQ intercalators can adopt four conformations (Figure 1B):  trans-
syn, trans-anti, cis-anti, and cis-syn.  A clear view of the conformations adopted by this linker, 
and the relation of these conformations to the structure of the side chain, can be important in un-
derstanding the binding of AQ to DNA.   
This conformation was first assessed by IR spectroscopy.  The IR of AQ I showed a sin-
gle N-H stretching band at 3338 cm
-1 
(Figure 4.2).  Previous studies have indicated that the N-H 
stretching band is sensitive to the conformation and that the cis- and trans-conformers usually 
appear approximately 20 - 40 cm
-1
 apart 
81
.  It can be assumed that the single sharp band for AQ 
I indicates the presence of only one amide isomer.  This is presumably the trans-conformer, be-
cause studies of other N-phenylamides have found that the trans-conformer is approximately 2.5 
kcal mol
-1
 energetically more favorable than the cis-conformer 
82-84
. 
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A single peak in the N-H region was seen in the 
1
H NMR 1D spectrum of AQ I (Figure 
4.3).  Shin et al. have seen completely separated signals (by approximately 0.5 ppm) of the N-H 
protons of the cis and trans amide isomers 
85
.  Evans and Miller also observed the separation of 
proton signals between the cis and trans isomers, in their examples of up to 3 ppm 
86
.  In our 
study, the observation of a single N-H peak in the NMR spectrum established the presence of 
only a single isomer.  In a ROESY spectrum, only two cross-peaks for the amide proton at 11.6 
ppm were seen, those for the H1 and H3 protons (the two protons ortho to the side chain at posi-
tion 2, Figure 4.4).  The lack of cross peaks between the H1/H3 protons and the methylene 
groups in the side chain indicated that only the trans isomer was present. 
4.1.4.2 Conformational Assignment of the Free AQ-amide in Solution  
Using the trans-anti isomers as the starting structures, rotations about the NH-CO ω-
amide bond and the AQ-NHCO Φ-bond for the free AQ I-IV amide were assessed.  Throughout 
the 50 ns simulations, there were no observations of cis-trans isomerization of the ω-bond, as 
measured by the torsional angle between the NH and CO groups (Figure 4.5); the trans isomer 
was the only species seen.  Cis/trans isomerization is an extremely slow process due to the exist-
ence of a large rotational barrier of the ω-bond, in the range of 15 - 20 kcal mol-1 81, 84.  The ab-
sence of rotation about the ω-bond in our study was therefore not surprising.   
The MD simulations showed free rotation about the AQ-NHCO Φ-bond.  The distribu-
tion of dihedral angles about the Φ-bond for AQ I-IV showed ensembles of amide conformations 
centered at ±45
o
 (designated trans-syn) and ±135
o
 (designated trans-anti) (Figure 4.6, top).  We 
note that a modeling study on an amido-anthraquinone with a different side chain found a pre-
ferred amide conformation of 0
o
 
29
.  In our work, the free energy profile of the dihedral angles 
87
 
for the Φ-bond showed that the trans-syn and trans-anti isomers were similar in energy (Figure 
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4.6, bottom).  The lack of substituents at the H1 and H3 positions on the AQ ring resulted in sim-
ilar probabilities of sampling both conformers. 
To assess the binding characteristics of the AQ ligands to DNA, the trans-anti conformer 
of each was docked between the second and third base pairs of the DNA hairpin.  The AQ-
ligands were oriented so that the side chain was in the minor groove, as observed with other 
anthracene molecules binding to DNA 
66, 88-94
.  The starting point of our analyses, chosen to be 
10 ns, allowed the system to equilibrate further.   
Figure 4.7 shows the stacking interactions of the AQ I-DNA complex, where only the 
four surrounding base pairs (C1:G16, G2:C15, C3:G14, and G4:C13) in close contact with the 
ligand are drawn for clarity.  The initial starting structure for the simulation had the AQ perpen-
dicular to the base pairs, based on other examples such as nogalamycin 
66
, daunomycin 
88
, and 
idarubicin 
89
.  During the simulation, AQ I reoriented to a position in which it was stacked al-
most parallel to the DNA base pair axis.  This geometry resulted in extensive chromophore-base 
overlaps, with the side chain components coming close to the sugar-phosphate groups in the mi-
nor grooves.  The geometry was presumably influenced by favorable DNA interactions with the 
quinone oxygens of the AQ, as well as the amido and amino groups of the side chain.   In the 
binding of other AQ-ligands to DNA, Williams and Searle have suggested that nogalamycin 
binding to DNA is driven by favorable interactions of the side chains, especially between the 2”-
OH on the bicycloaminoglucose sugar and N7 of the nearby guanine 
66
.  Tanious et al. have pro-
posed that the substituent position on AQ ligands dictates the intercalative DNA binding geome-
try 
20
. 
The MD simulations showed restricted rotation about the AQ-NHCO Φ-bond when AQ I 
was bound to DNA (Figure 4.8A).  The trans-syn conformation was favored (-45
o
, carbonyl 
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pointed towards the terminus of the hairpin), but both trans-syn and trans-anti conformations 
were observed.  Visual inspection of the simulation showed that the NH of the AQ amide was 
closest to O4' of the C3 sugar.  About 70% of the structures had the NH and O4' atoms situated 
within H-bonding distance of one another (< 3 Å, Figure 4.8B).  This set of structures generally 
had the amide in the trans-syn conformation.  The remaining structures (30% of the simulation) 
did not have a hydrogen bond to the amide.  In these structures, the amide was generally in the 
trans-anti conformation and positioned such that it could not hydrogen bond with the O4' group 
(or other nearby hydrogen bond acceptors). 
Binding of AQ II-IV were similar to that of AQ I.  The AQ ring systems stacked almost 
parallel to the G2:C15 and C3:G14 base pair axis, similar to the geometry observed for AQ I.  
The side chain NH-amides sampled both the trans-anti and trans-syn conformations (Figure 4.8).  
The trans-syn conformer accounted for the majority of conformations.  However, in comparison 
to AQ I, as the side chain increased in length, a wider range of trans-syn conformers appeared (-
60
o
 to 15
o
 for AQ II and -60
o 
to 30
o
 for AQ III and AQ IV), some of which were not stabilized 
by a hydrogen bond between the NH-amide and O4' of the C3 sugar.  Overall, in comparison to 
AQ I, there was a decrease in correlation between the trans-syn conformer and the hydrogen 
bond between the NH-amide and C3 O4' groups. 
4.1.4.3 Electrostatic Interactions between the Ligand and DNA. 
For the AQ I-DNA complex, about half of the structures had an apparent electrostatic in-
teraction between the ammonium group in the side chain and the nearest phosphate group, C3 
(R2NH2
+ 
- PO4
-
 distances of ~ 3 to 4 Å, Figure 4.8C).  This interaction is presumably involved in 
helping to anchor the ligand into the DNA binding site. The other half of the structures had 
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R2NH2
+ 
- PO4
-
 distances of > 4 Å.  There was moderate correlation between the shorter R2NH2
+ 
- 
PO4
-
 distances and hydrogen bonding of the amide NH to O4' of the C3 sugar. 
The AQ II-IV derivatives maintained distances of ~ 3 to 4 Å between the R2NH2
+
 group 
and PO4
-
 of C3 for about 40 - 50% of the simulation (Figure 4.8C).  This interaction, like that for 
AQ I, is presumably involved in helping to anchor the ligand into the DNA binding site.  A de-
crease in the correlation between the trans-syn conformer and hydrogen bond between the NH-
amide and C3 O4' groups as well as some decrease in the percentage of apparent electrostatic 
contacts between the R2NH2
+
 and C3 PO4
-
 groups may be attributed to other structures favored 
by the side chain in AQ II-IV. 
4.1.4.4 Conformational Analysis of the Side Chains in AQ I-IV. 
Visual analyses of the dynamic trajectories of both the free and bound AQ ligands in so-
lution showed that the side chains were very flexible (snapshots of AQ I and AQ IV are shown 
in Figure 4.9).  We noted that the free ligands exhibited a wider range of motion, sampling more 
conformers compared to the bound ligands.   
Using the distance between the ammonium group and terminal methyl in the side chain 
(R2NH2
+
 - CH3 distances) as a metric, we observed that the side chain had a shorter average dis-
tance in the free AQ as compared to the DNA-bound AQ in each case (Figure 4.10).  The effect 
is fairly small for AQ I, with the bound AQ having only a slightly greater average distance than 
the free AQ.  The difference became greater as the side chain lengthened.  Free AQ IV had a 
fairly equal distribution of conformers with distances of 5 - 13 Å whereas bound AQ IV had an 
ensemble of favored conformers at a significantly greater distance: 10 - 14 Å.  The difference in 
the free and bound forms was in part due to the presence of DNA restricting the conformational 
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space of the side chain.  For all the bound AQ ligands, the side chain spent more time sampling 
conformations away from the DNA groove. 
In addition, we noted an increased localization of the PEG side chain in the DNA groove 
as the chain length increased (Figure 4.11).  The distances between the second oxygen of the side 
chain and DG5:O2 of the DNA were used as a metric for groove localization.  Structures having 
distances of less than 5 Å between the side chain and DNA were considered localized in the 
DNA groove; these accounted for about 25% of the simulation for AQ IV.  Snapshots of AQ IV 
with the side chain in the groove are shown in Figure 4.12.  The significant number of PEG 
structures in the DNA groove was an indication of interactions between the PEG side chain and 
the DNA.  These interactions further restrict motions of the side chain and thereby contribute un-
favorably to the entropy.  PEG is not generally considered to interact with DNA; however, the 
forced high local concentration of the PEG side chain in the DNA groove could favor these in-
teractions.   
We quantitated the entropies of the side chains using Schlitter’s equation, [2] 78.  For the 
free AQ I-IV ligands, the configurational entropies increased from ~47 to 71 kcal/mol as the side 
chain length increased (Table 4.1).  The increased entropy along the series AQ I-IV was attribut-
ed primarily to the increase in the number of rotatable bonds in the side chain.  The calculated 
entropies of the side chain for the bound AQ I-IV ligands (T∆Sbound) ranged from ~43 to 65 
cal/mol.  Using the equation T∆Sconf = T∆Sbound - T∆Sfree, changes in entropy of -3.9 to -6.3 
kcal/mol were obtained for AQ I-IV binding to DNA.  This indicated a decrease in entropy upon 
binding to DNA, becoming more unfavorable along the series AQ I to AQ IV.  This T∆Sconf 
term can be compared to the loss in translational and rotational degrees of freedom upon ligand-
host complex formation, the TΔSt+r term in ΔGt+r ([2]).  The TΔSt+r term is estimated as 14.4 ± 3 
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kcal/mol 
95
.  The T∆Sconf contributions of AQ I-IV are therefore significant when compared to 
TΔSt+r.  The free energy of conformational change for intercalators bearing a long or flexible 
side chains can contribute significantly to the overall free energy of binding of a ligand to DNA. 
4.1.4.5 Side Chain Conformation and Water Bridges. 
The difference in the side chain conformations between the bound and unbound AQ can 
also be viewed from the standpoint of water interactions.  We analyzed the data set in terms of 
the internal water bridges within the side chain.  Two types of internal water bridges were ob-
served throughout the simulation, 1:2 bridges (bridging adjacent ether oxygen atoms) and 1:3 
bridges (bridging every other ether oxygen).  These bridges are commonly seen in simulations of 
PEG in water; leading references are found in Wahab et al. 
96
 and Juneja et al. 
97
.   
Looking first at AQ IV free in solution, water bridges were maintained for > 85% of the 
simulation.  The majority (~ 75%) of the structures had at least two water bridges (Table 4.2).  
The situation changed when AQ IV was bound to DNA.  Considering first the structures in 
which the side chain was localized in the DNA groove (distances of less than 5 Å between se-
cond oxygen of the side chain and DG5:O2 of the DNA), we saw that only approximately 25% 
of the structures had two or more water bridges, the other structures had either one or no water 
bridge.  The set of structures with the side chain not localized in the groove had approximately 
half of its structures with two or more water bridges.  Overall, binding to DNA appeared to de-
crease the number of internal water bridges in the AQ side chain.   
Fewer ether oxygens in the side chain resulted in fewer water bridges, as expected.  For 
the bound AQ IV side chain, 1:2 and 1:3 water bridges were maintained for > 65% and 20% of 
the simulation, respectively.  The bound AQ III ligand maintained 1:2 and 1:3 water bridges for 
approximately 40% and 7% of the simulation, respectively.  The 1:2 water bridges in AQ II were 
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maintained for only 25% of the simulation; AQ I cannot form bridges.  Overall, comparing the 
free and bound AQ ligands, the free ligands showed 10 - 25% more 1:2 water associations than 
the bound, but the 1:3 water bridges were about the same in both forms.  Water occupancy of the 
free side chain ether oxygens, counting both bridged and nonbridged waters, ranged from a low 
of about 50% in AQ I to a high of greater than 80% for each of the ether oxygens in AQ IV. 
4.1.4.6 Bridged Waters between the Ligand and DNA. 
To probe the possible mediating role of water molecules, we identified water molecules 
that were involved in H-bonds between the ligand and DNA (distances ≤ 3.5 Å).  For all of the 
series, both carbonyl oxygen atoms on the AQ chromophore were significantly hydrated 
throughout the simulation.  The oxygen pointing in the minor groove (bridged to G14 and C15) 
was hydrated for greater than 90% of the simulation while that in the major groove (bridged to 
G2) was hydrated for over 80% of the simulation.  The ammonium hydrogens also participated 
in water-mediated H-bonds with the C3 phosphate; however, this was seen for less than 10% of 
the simulation.  The amide carbonyl oxygen had bound water occupancy greater than 90%, but 
these bound waters were not seen to mediate interactions with the DNA.  The role of DNA hy-
dration in structure stabilization and mediating drug-DNA interactions in DNA-ligand complexes 
have been discussed 
98-99
.  In general, bridging waters can play an important role in the structure 
of AQ-DNA complexes. 
4.1.4.7 Hydration of the AQ-DNA Complexes. 
To assess structural water, the simulations were analyzed for site occupancy, taken as two 
or more times bulk water density.  As an example, Figure 4.13 shows high occupancy water 
solvation sites for AQ I and AQ IV.  The most obvious structural waters were along the spine of 
hydration in the minor groove.  The positioning of the waters in the DNA minor groove for AQ I 
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and AQ IV were somewhat different.  Higher density water regions appeared to decrease as the 
side chain increased in length.  The interaction of the PEG side chain in AQ IV with the DNA 
groove seemed to influence the binding of water to the DNA groove.  Ligands that bind to the 
minor groove of DNA have been shown to affect the hydration of the groove, e.g., Hoechst 
33258 
100
, DAPI 
101
, the benzimidazole derivatives DB183 and DB185 
102
, and netropsin 
103
. 
It has previously been noted that small changes in the side chains of an intercalator can 
make significant changes in the water associated with the DNA-intercalator complex.  For exam-
ple, the adriamycin-DNA complex binds 18 more water molecules than does the daunomycin 
complex, although these anthraquinone derivatives differ only by a single hydroxyl group in the 
side chain 
104
.  Propidium binds DNA with six more water molecules in the complex than does 
ethidium 
105
. 
4.1.5 Conclusions. 
We have used MD simulations to assess the DNA binding characteristics of four homol-
ogous AQ intercalators bearing increasing lengths of PEG side chain.  In all four AQ-ligands, the 
amide was found mainly in the trans-syn conformation, generally stabilized by hydrogen bond-
ing interactions between the DNA and amide.  An apparent electrostatic interaction between the 
side chain ammonium group and the close-by C3 phosphate was seen in all four AQ-DNA com-
plexes; however, the length of time it was maintained decreased as the side chain increased in 
length. This is presumably due to an increasing number of other favorable conformers as the side 
chain becomes longer.    
Our MD simulations indicated increasingly unfavorable entropic contributions to the free 
energy of binding as the side chain became longer.  This seemed to be due in part to restricted 
conformational space and perhaps in part due to increasing localization of longer chains in the 
124 
DNA groove.  The magnitude of these entropic contributions can be significant, especially for 
long and flexible side chains.   
DNA binding of this AQ series resulted in a forced high local concentration of PEG in 
the DNA groove.  PEG is widely used as an osmolyte in DNA studies and generally viewed as 
having minimal interaction with the DNA.  We found that AQ IV had a significant percentage of 
structures localized in the DNA groove.  This may be an indication of PEG interacting with the 
DNA groove.  There was a high correlation between conformations with the side chains local-
ized in the DNA groove and a decrease in the number of internal water bridges.  The decrease in 
the number of internal water bridges observed between the free and bound ligands was presuma-
bly due to the formation of favorable structures with the DNA.   
Overall, the AQ and PEG side chains bring together multiple conformational preferences 
to define ligand binding to DNA.  Comparison of free and bound AQ IV indicated that interac-
tions with the DNA have a significant effect on the conformations of the side chain.  The effects 
of intramolecular cross-linking via water bridges may important when designing nucleic acids 
conjugated to PEG groups.  These studies on DNA-intercalator binding can aid in the develop-
ment of new DNA binding agents. 
4.2 Unpublished Data. 
Figure 4.15 gives a summary of the hydrated oxygens in AQ IV; Table 4.3 gives a sum-
mary of the percent time each oxygen is hydrated in AQ I-IV, both free and bound. 
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Figure 4.1: (A) Chemical structures of anthraquinone amides, AQ I – IV. (B) Representation of 
the amide bond conformers, drawn as planar structures. 
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Figure 4.2: Representative snapshot of the interaction of 
AQ I with the DNA hairpin.   
The R2NH2
+
 - PO4
- 
and NH-O4' interactions are shown.  
The amide is in the trans-syn conformation. 
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Figure 4.3: Analysis of the binding of AQ I (left) and AQ IV (right) to DNA; data are  
presented as a function of time.   
(A) Rotation about the AQ-NHCO Φ-bond. (B) Distance between NH-amide and O4' of the C3 sug-
ar of DNA. (C) Distance between the side chain ammonium group (R2NH2
+
) and PO4
-
 of C3.  
 
Figure 4.4: Composite of 250 snapshot geometries of AQ I (top) and AQ IV (bottom) 
between 10 to 50 ns for the free (left) and bound (right) ligands.  
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Figure 4.5: Analysis of localization of 
AQ II-IV side chain in the DNA minor 
groove; data are presented as a function 
of the distance between the second oxy-
gen of the side chain and DG5:O2 of the 
DNA.  
                                                                                                                         
  
Figure 4.7:  Subset of AQ IV structures with 
the side chain localized in the DNA groove (dis-
tances of less than 5 Å between second oxygen 
of the side chain and DG5:O2 of the DNA).  
Shown are 250 shots taken randomly from this 
subset collected between 10 and 50 ns.    
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Figure 4.6: Analysis of the side chain confor-
mation of AQ I-IV; data are presented as a func-
tion of distances between the R2NH2
+
 group and 
terminal methyl of the side chain.   
The dashed lines are the free AQ ligand and the 
solid lines are the bound AQ ligand.  
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Figure 4.8: Minor groove view of the hydration of the AQ I-DNA complex (left) and AQ IV-
DNA complex (right).  
The contour thresholds correspond to 2.0 or more times the average bulk water density (shown in 
key) during the simulation.  The DNA and AQ ligand for both AQ I and AQ IV are single snap-
shots representing the average structure of these complexes. 
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Figure 4.9 (S1): Infrared spectrum of neat AQ I. 
 
 
Figure 4.10 (S2): 
1
H NMR spectrum of AQ I in CDCl3. 
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Figure 4.11 (S3): 2D ROESY NMR spectrum of AQ I.   
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Figure 4.12 (S4):  The NH-CO ω-dihedral angle as a function of time for the AQ I free ligand. 
 
 
0
125
250
375
500
F
re
q
u
en
cy
-1
8
0
-1
5
0
-1
2
0
-9
0
-6
0
-3
0 0
3
0
6
0
9
0
1
2
0
1
5
0
1
8
0
Angle of the AQ-NHCO bond (degrees)
-10
-12
-14
-16
-18
-20
F
re
e 
en
er
g
y
, 
(k
ca
l 
m
o
l-
1
)
trans-anti      trans-syn         trans-syn trans-anti 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 (S5): Probability plot of the AQ-
NHCO Φ-dihedral angle for the free AQ I lig-
and (top).  Conversion of the probability plot to 
its corresponding free energy profile (bottom). 
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Figure 4.15: Hydration of AQ-ligand. 
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Figure 4.14 (S6): Analysis of the binding of AQ II (left) and AQ III (right) to DNA; data are 
presented as a function of time.   
(A) Rotation about the AQ-NHCO Φ-bond. (B) Distance between NH-amide and O4' of the C3 sugar 
of DNA. (C) Distance between the side chain ammonium group (R2NH2
+
) and PO4
-
 of C3.  
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Table 4.1: Entropy change of the AQ I-IV side chain when free in solution and bound to DNA. 
Ligand T∆Sfree 
(kcal/mol) 
T∆Sbound 
(kcal/mol) 
T∆Sconf 
(kcal/mol) 
AQ I 46.5 42.6 -3.9 
AQ II 52.3 47.8 -4.5 
AQ III 60.2 55.7 -4.5 
AQ IV 71.1 64.8 -6.3 
 
Table 4.2: Hydration of the AQ IV side chain when free in solution and bound to DNA. 
Side chain confor-
mation 
Zero wa-
ter bridge 
(%) 
One water 
bridge (%) 
Two water 
bridges 
(%) 
Three water 
bridges (%) 
Four wa-
ter bridges 
(%) 
Bound AQ IV local-
ized in the DNA 
groove* 
28 44 20 6 1 
Bound AQ IV not lo-
calized in the DNA 
groove† 
16 34 32 14 3 
Free AQ IV 14 12 45 25 4 
* Localization was defined by using distances of < 5 Å between the second oxygen of the side   
  chain and DG5:O2 of the DNA . 
† Defined by using distances of ≥ 5 Å between the second oxygen of the side chain and DG5:O2   
  of the DNA. 
 
Table 4.3: Hydration of the oxygens in AQ I-IV when free in solution and bound to DNA. 
  AQ I  AQ I AQ II AQ II AQ III AQ III AQ IV AQ IV 
  Free Bound Free Bound Free Bound Free Bound 
O22 99 95 97 96 98 93 96 91 
O37 89 92 93 90 94 92 92 90 
O23 88 86 85 87 83 81 84 81 
O4             94 72 
O3          88 67 92 64 
O2     68 53 82 63 86 56 
O1 53 49 65 52 71 50 86 67 
Internal 
Bridges                 
O1-O2     37 25 33 26 57 40 
O2-O3         47 35 24 18 
O3-O4             62 39 
O1-O3         11 7 17 16 
O2-O4             21 17 
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5 INVESTIGATION OF THE KINETICS OF A SERIES OF THREADING 
ANTHRAQUINONE INTERCALATORS  
5.1 Introduction  
Threading intercalators represent a class of high affinity DNA binding agents that interact 
by inserting the chromophore between the DNA bases and locating one substituent into each 
groove 
1-7
.    For association as well as dissociation to occur, one of the bulky and/or charged 
side chains must pass through the DNA bases; this requires significant conformational changes 
in the DNA structure and, in some cases, opening of at least one base pair 
5, 8
.  These structural 
constraints generally lead to slow association and dissociation rates compared to classical 
intercalators 
2-3, 5, 7, 9-12
.   The major classes of threading intercalators include naphthalene 
diimides 
13-28
, anthraquinones 
1, 29-34
, acridines 
35-43
, and binuclear ruthenium complexes 
10, 12, 44-
47
.  The kinetics of threading intercalators have been postulated to be a feature in their cytotoxic 
properties for some members of this class  
38, 40, 42-43, 48-51
.  
The naphthalene diimide (NDI) derivatives have become significant players in the field 
of threading intercalators, due to synthetically easy derivatization of the parent naphthalene 
diimide structure 
13-28
.  Early kinetic studies showed an apparent association rate constant of ka 
~1.4 x 10
5
 M
-1
 sec
-1
, and dissociation rate constant of kd ~ 0.20 sec
-1
 (dependent on the salt con-
centration) for small members of this class with symmetrical side chains 
15
.  Iverson’s group has 
more recently developed a new class of poly-threading intercalators by connecting several NDI 
units via flexible linkers 
9, 28
.  Their efforts involved developing longer poly-intercalators as well 
as investigating linkers of various compositions in an attempt to improve the intercalator’s speci-
ficity.  The dissociation half-life of a threading tetra-intercalator was ~16 days 
9
.  Dissociation 
142 
rates correlated with relative affinities for some members of this class 
28
.  The group also showed 
that altering the symmetry, direction, and charge in the linker allowed discrimination of up to 14 
bp DNA binding sites that diﬀered by 1 or 2 base pairs linkers by as much as 30-fold 28.  
A series of binuclear ruthenium complexes with different auxiliary and bridging ligands 
have recently been investigated for their threading intercalating properties.  Members of this 
class with very slow intercalation kinetics have been used to study the effect of the ligand’s na-
ture on their threading efficiency.  In this context, several groups have investigated the effect of 
the ligand’s chirality on the threading mechanism and rates 12, 52-54.  Onfelt et al. have studied the 
interactions of two bis-threading ruthenium enantiomers with ct-DNA 
54
.  The two enantiomers 
had similar thermodynamic affinities, but varied considerably in their binding kinetics.  Dissocia-
tion from ct-DNA was markedly faster and also more dependent on the ionic strength for one of 
the enantiomers, possibly due to differences in the conformational changes of the DNA (which 
was thought to define the rate-limiting step).  Andersson et al. have also shown differences in the 
rates due to the chirality of the ligand 
12
.  They postulated that for shorter bridging ligands, the 
interactions between the non-intercalating side chain and DNA became increasingly important 
and dominated the enantio-selectivity.  In contrast, for longer bridging ligands, the chirality 
around the intercalating part seemed more important.  Additional work in the area of the kinetics 
of metal-polypyridine complexes with DNA has been reviewed by Biver et al. 
55
 and by 
Wilhelmsson et al. 
56
 
There have also been several studies on the effect of structural changes in large rutheni-
um complexes on the DNA binding mechanism.  Nordell et al. have investigated the mechanism 
of threading ruthenium complexes, one bearing two ruthenium phenanthroline side chains and 
the other, two bipyridine groups 
57-58
.  The mechanism of the bipyridine system was proposed to 
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be an initial formation of a semi-intercalated species which slowly converted to the final thread-
ed complex.  In contrast, binding of the phenanthroline analogue fit a mechanism of two parallel 
paths.  One pathway passed through a semi-intercalated complex before the final threaded state, 
and the other through a groove-aligned complex before the fully intercalated state.  The steric 
hindrance of the larger phenanthroline ligand presumably disfavored the semi-intercalated path-
way.  Li et al. have studied four ruthenium threading derivatives with different bulky quaternary 
ammonium substituents to find relationships between molecular structure and intercalation kinet-
ics 
59
.  The intercalation kinetics were found to be dependent on both the charge and the distance 
between the bulky substituent and the ruthenium center.  They proposed that the kinetic proper-
ties of the threaders were important for consideration as a chemotherapeutic agent.   
Intercalators with large and rigid side chains have been used to probe the relationship be-
tween DNA dynamics and the threading process.  For example, dissociation from a long stretch 
of alternating A–T can be more than three orders of magnitude greater than that from a mixed 
sequence, due to the increased structural flexibility of the AT base pairs 
57, 60
.  Studies of binu-
clear ruthenium complexes with AT-rich hairpins revealed a significant increase in the threading 
association rate for sequences with AT base pairs for more than one helix turn of the B-DNA 
61
.  
The dissociation rate constants did not show a pattern in this regard and the mechanism did not 
depend on an open end of the hairpin.  The threading process was also enhanced by loops or 
mismatches in the sequence.  Recently, Kogan et al. have shown that a binuclear ruthenium 
complex can thread efficiently into reannealed polymorphic DNA in comparison to native DNA, 
leading to the conclusion that the threader is binding to local areas of the DNA that do not have 
duplex structure 
62
.  A dimeric ruthenium complex has been found to thread into negatively 
supercoiled plasmid DNA two orders of magnitude more quickly than into the cleaved linear 
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form of the DNA, indicating that torsional strain can have a significant controlling effect on the 
kinetics of intercalation 
45
.  In other work, threading intercalation into lambda DNA stretched 
with optical tweezers was interpreted in terms of binding to one or more melted base pairs 
46
.  
The association mechanism may involve slow relaxations in the conformations of the initially 
bound species 
47
. 
The final DNA structure in these DNA-intercalator complex need not be a duplex.  For 
example, Choudhury et al. have found that a platinum-acridine bisintercalator can stabilize either 
the classical B-form or a non-B-form of the DNA depending on the stereochemistry around the 
metal center and the nature of the acridine’s side chain 42.  In one instance, a structure with base 
pairing of a Hoogsteen nature was observed.  Other work has shown that some systems have 
complicated mechanistic patterns.  For example, an acridine with an appended polyamine center 
shows two binding processes depending on the DNA/intercalator ratio, with the binding mode at 
low ratios interpreted largely in terms of external binding and that at higher ratios in terms of in-
tercalation of the aromatic moiety 
63
.  
The majority of the studies to date involve changes in the three dimensional structure of 
the side chain, often with rigid groups that lie in the DNA grooves in the final structures.  In the-
se cases, the mechanism of the intercalation is intrinsically tied with the geometry of the final 
structure.  In our study, we are interested in widening our understanding of the threading process 
by studying a series of complexes in which the final structures of the intercalated complexes, 
with respect to placement of the intercalating moiety itself in the DNA and their side chains, are 
very similar.  This is a series for which the threading process is essentially uncoupled from the 
final structures of the intercalated species.  To achieve this, we have studied a series of four ho-
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mologous threading intercalators, which differ only in the lengths of the appended polyethylene-
based side chains.   
5.2 Work to be published 
Investigation into the Kinetics of a Homologous Series of Threading Intercalators 
Binding to DNA 
5.2.1 Abstract  
The association rate constants of a homologous series of anthraquinone intercalators with 
calf thymus DNA have been studied using stopped-flow spectrophotometry.  The threading 
mechanisms of the anthraquinones’ binding to DNA showed sensitivity to the side chain length 
of the molecule.  The curves for the three longer side chains were bi-exponential.  We propose a 
three step mechanism which involves formation of an external bound anthraquinone-DNA com-
plex followed by intercalation of the anthraquinone, and isomerization to another complex with 
similar thermodynamic stability.  The kinetic curve for the shortest side chain was mono-
exponential, probably corresponding to the first two steps of the three step mechanism.  Our 
work indicates the apparent mechanistic consequences of even small changes in a flexible side 
chain of a DNA intercalator. 
5.2.2 Introduction  
The intercalation of molecules into DNA continues to be of interest in terms of the design 
of pharmaceutical agents, toxicity, and the fundamental biophysical processes that are involved 
in the intercalation event 
2-3, 6-7, 64-68
.  Threading intercalators are a subset of intercalators that 
bind with side chains in both the major and minor groove 
1-6
.  For association as well as dissocia-
tion to occur, one of the bulky and/or charged side chains must pass through the DNA bases, 
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which requires significant conformational changes in the DNA structure and may give complex 
mechanistic pictures.  One of the earliest kinetic studies was on nogalamycin, an anthracycline 
antibiotic with appended sugars 
5, 30, 69
.  The association kinetics are complex and require not less 
than three exponentials to fit its profile with ct-DNA 
69
.  Other studies have also been conducted 
with a cis-platinum threading derivative of proflavine 
70-71
.  The kinetic process for this deriva-
tive was discussed in terms of a three step mechanism in which an initial external complex is 
formed followed by partial and then full intercalation.  Much of the recent work in the area, 
however, has focused on large intercalators consisting of aromatic units surrounding a central 
metal atom 
5
.  Some of these structures have very slow on (t1/2 = 132 min into AT-rich DNA) and 
off (t1/2 = 17 min) rates 
60
.  It has been shown that the changes to the intercalator’s structure can 
result in changes of the binding mechanism 
12, 57, 59-60
.  It is clear that even complex structures 
can eventually adopt a fully intercalated geometry, as shown by a study of a threading tetra-
bisintercalator 
9
.  
For the design of new pharmaceutical compounds, it is of interest to understand how 
small molecules with flexible side chains intercalate into DNA.  Presumably both the ligand and 
DNA are required to change their conformation upon binding.  In this work, we have focused on 
2,6-substituted anthraquinones, which adopt a threading geometry 
29, 72
.  Early work on 
anthraquinones with small flexible side chains showed association rates that were ≤ 2 x 105 M-1s-
1
 
29.  The dissociation rates were ≤ 5-6 s-1.  The anthraquinones required two exponentials to fit 
their binding kinetics, with differences between the two rate constants of <4 fold for both associ-
ation and dissociation kinetics. 
In the current study, we were interested in probing the effect of larger flexible side 
chains.  This can allow evaluation of more complex mechanisms of intercalation where the main 
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differences are in the threading processes per se; that is, a situation in which the threading pro-
cess is essentially uncoupled from the final structures of the intercalated species.  To achieve 
this, we have studied a series of four homologous threading intercalators, which differ only in the 
lengths of the appended polyethylene-based side chains.  The final structures are expected to be 
very similar with respect to placement of the intercalating moiety itself in the DNA.   
5.2.3 Results and Discussion 
The compounds used in our study, AQT I – AQT IV (Fig. 1),  were synthesized accord-
ing to the procedure reported by McKnight et al. 
72
  We have used a combination of fluorescence 
spectroscopy 
73
 and stopped-flow kinetics 
74
 to assess the equilibrium binding parameters and the 
association and dissociation rate constants for the binding of the four anthraquinone ligands to ct-
DNA.       
Figure 2 shows the equilibrium titration of AQT IV in the presence of ct-DNA; the 
anthraquinone fluorescence signal became less emissive upon binding to DNA.  The equilibrium 
constant (4.0 x 10
4
 M
-1
) and the number of bases per binding site (~4) were obtained by fitting 
the titration data to Supplementary Equation 2.  The binding constant of AQT IV to AT- and 
GC-rich DNA hairpins was previously determined to be 19 x 10
4
 M
-1
 (n = ~3) and 9.0 x 10
4
 M
-1
 
(n = ~4), respectively, using surface plasmon resonance 
72
.   The small differences presumably 
reflect the different DNA and techniques used.  Equilibrium fluorescence titrations of AQT I, 
AQT II, and AQT III gave binding constants of 3.3 x 10
5
 M
-1
 (n = ~3), 1.6 x 10
5
 M
-1
 (n = ~3), 
and 0.93 x 10
5
 M
-1
 (n = ~3), respectively (Supplementary Figures 1-3).   
The binding process for AQT IV to DNA showed distinct fast and slow kinetic phases.  
For both phases, the derived rate constants showed a hyperbolic dependence on the concentration 
of DNA (Figure 3).  This type of dependence indicates a rapid equilibrium followed by a kinet-
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ically measureable step.  The simplest model consistent with the data is given in equation 1; 
equations appropriate for non-linear least squares fitting are in the Supplementary Data.  It 
should be noted that all fitting takes into account the site size of the DNA-threader complex, 
based on the McGhee-von Hippel formalism 
75
 as developed by Jovin and Striker 
76
.  
 
eq 1 
 
For AQT IV, about 60% of the fast phase was completed at the highest concentration of 
DNA (130 µM) within the instrument’s dead time.  Fitting the observed data with a site size of 4 
gave an equilibrium binding constant, K1 of 5.9 x 10
4
 M
-1
, an association rate constant, k2 of 340 
s
-1
, and dissociation rate constant, k-2 of 71 s
-1
.  A site size of 3 did not give a good hyperbolic fit; 
a site size of 5 gave values of K1 = 4.5 x 10
4
 M
-1
, k2 = 290 s
-1
, and k-2 = 115 s
-1
.  These data indi-
cate the sensitivity of the calculated values to the site size assumed for the complex.     
Fitting of the slow phase gave an equilibrium constant for the first two steps of 4.1 x 10
4
 
M
-1
, a k3 of 21 s
-1 
and a k-3 of 19 s
-1
.  The slow phase, while not as sensitive to site size as the fast 
phase, also displayed differences in the fitted kinetic parameters.  The overall calculated equilib-
rium binding constant K123 = K1 [1+K2(1 + K3)] 
77
 was ~4.3 x 10
5
 M
-1
.  This was within a factor 
of approximately 10 of the equilibrium constant determined by direct titration.  The differences 
in the calculated equilibrium constant and that measured from static fluorescence titration are 
presumably due to partial completion of the reaction within the instrument’s dead time, to the 
sensitivity of the calculated parameters to the DNA binding site size, and to the mathematical 
approach, which collapses binding at many similar, but not equivalent, sites to a simple four-
component model.  
AQ + DNA               AQ-DNA1              AQ-DNA2              AQ-DNA3
K1 k2
k-2
k3
k-3
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The intercalation kinetics for both AQT II and AQT III showed a fast phase followed by 
a slow phase, similar to AQT IV.  In these cases, however, the first phase was significantly fast-
er than for AQT IV, with extents of completion that precluded good fitting of this phase (Sup-
plementary Figures S4 and S5).  The second phase of AQT II and AQT III binding to DNA was 
slower.  Fitting to equation 7 (Supplementary Data) showed similar association and dissociation 
rate constants for these two homologs (Table 1).  These compounds fit the intercalation model 
for AQT IV. 
The intercalation model we propose for the three longer homologs involves initial for-
mation of a weak electrostatic complex (AQ-DNA1).   Conformational changes in the DNA open 
an intercalation site allowing the anthraquinone to thread through the opening to give AQ-DNA2.  
This slowly isomerizes to form AQ-DNA3.  The second step in equation 1 (formation of the AQ-
DNA2 complex) was visualized only for AQT IV.  This is presumably simply a function of the 
longer side chain in this system, which slows its binding rate to DNA.  We have previously 
shown that the long polyethylene glycol side chain of AQT IV adopts a helical conformation, 
and it is possible that this propensity may also affect the kinetics in this system 
78
.   
A slow phase, with forward and reverse rate constants of about 20 s
-1
 and a K3 equilibri-
um constant of about 1, was observed for all three of AQT II, AQT III, and AQT IV.  Similar 
K3 equilibrium constants have been observed for the anthraquinone based intercalator 
daunomycin 
77
  as well as proflavines 
70, 79
.  The most likely explanations are a conformational 
rearrangement of the DNA or redistribution of the ligand to other sites on the DNA.  In the for-
mer instance, an AQ-DNA complex would be formed in which the ligand is only partially inter-
calated.  This would be in equilibrium with an AQ-DNA complex that is fully intercalated and 
the ligand is now enveloped by the DNA bases.  A second explanation is that the intercalator ini-
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tially finds a kinetically favorable site, and gradually rearranges to a suite of complexes in which 
the intercalator is bound to other sites that are of similar thermodynamic stability.  It has been 
shown that intercalation into AT-rich sites is generally more kinetically favorable than into GC-
rich sites 
60-61, 80-82
.  Previous work on rigid threading intercalators has also found a significant 
kinetic preference for AT-rich DNA sequences.  However, in that we have previously shown that 
these anthraquinone threaders preferentially bind to AT-sites rather than GC-sites in a thermody-
namic sense 
72
, redistribution to a GC-site is presumably not thermodynamically favorable in this 
instance.  It may be, however, that the initial kinetic complex is the result of binding to a stretch 
of AT-rich sequence, while the final complex is redistribution of the bound ligand more evenly 
along the DNA (perhaps still with preference for AT sites).   
In contrast to AQT II-IV which fitted to a double exponential equation, the association 
kinetics of AQT I to ct-DNA only required a single exponential to fit the reaction trace.  The ap-
parent association rate was linearly dependent on the DNA concentration (Figure 4).  The reac-
tion was fast enough that about 60% of the process (at the highest concentration of DNA, 130 
µM) occurred during the dead time of the instrument.  Fitting the observed trace gave an associa-
tion rate constant, k1, of 5.2 x 10
5
 M
-1
s
-1
 and a dissociation rate constant, k-1, of 58 s
-1
 (n = 3, and 
similar for n = 4 and 5).  The simple kinetic data obtained correspond to an apparent one-step 
mechanism for AQT I binding to DNA. 
One possibility for the observation of the simple linear dependence kinetics is that we are 
observing only the first two steps of equation 1 with a small value for K1.  Indeed, the data would 
have a linear dependence on the concentration of DNA if the first equilibrium binding constant, 
K1, were ≤10
3 
M
-1
, and association rate constant for intercalation, k2, had a value >300.  A K1 
value of ~10
2
  - 10
3 
M
-1
 has been previously estimated for formation of an electrostatic complex 
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between ligands and DNA
 83
 and this value for k2 is in line with that observed for the other hom-
ologs in the series.  The apparent simplicity of the kinetics for AQT I is presumably because the 
side chains of this threader can easily move through local openings in the DNA that are smaller, 
and formed more frequently, than those required by the larger homologs in the series.   
5.2.4 Conclusion 
In conclusion, our study of the binding mechanism of anthraquinone threading 
intercalators to DNA has shown a high sensitivity of rates on the ligand’s side chain length.  The 
three derivatives bearing longer side chains bound via a three step mechanism.  For all of them, 
the last step was a slow process, independent of the concentration of DNA, which had forward 
and reverse rate constants of about 20 s
-1
.  Although the shortest side chain ligand, AQT I, ap-
peared to bind via a simple one step mechanism, it is likely that this process is the first two steps 
of the three step mechanism (with the last, slow, step, not observed for this ligand).  Threading 
intercalation of ligands into DNA is influenced by two main factors: the DNA dynamics and the 
nature of the ligand.  Smaller side chains are able to thread through small local openings in the 
DNA bases created by thermal fluctuations.  This results in faster association rates, and an ap-
parently simpler binding mechanism.  Longer side chains are not able to thread through the local 
openings in the DNA, and therefore must either find locally melted regions or bind to the DNA 
and facilitate conformational changes in its structure.  After initial threading of the ligand, the 
complex isomerizes to another complex with very similar energy, most seemingly via redistribu-
tion of the ligand more evenly along the DNA.  However, this step may be the ligand becoming 
fully intercalated into the DNA.  Such schemes have been observed before, but generally in 
complexes with rigid side chains designed to slow the threading intercalation process.  Our work 
152 
shows that even small changes in a flexible intercalator side chain can lead to significant changes 
in the apparent intercalation process.    
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Figure 5.1 Threading anthraquinone intercalators, AQT I - AQT IV used in this study. 
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Figure 5.2: Fluorescence spectral titration of ct-DNA with 3.3 
µM AQT IV in MES10 buffer, 0.15 M NaCl, pH 6.24 and 25 
o
C 
(λex:354 nm; λem:536 nm).   
Top: Fluorescence spectra of AQT IV with ct-DNA at various 
DNA:AQT IV ratios (ri = 0 to 60; concentration of DNA given 
in base pairs).  Bottom: The observed change in emission inten-
sity at 536 nm as a function of the concentration of ct-DNA were 
fitted with a multiple-site binding model to obtain an equilibri-
um binding constant and the binding site size.   
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Figure 5.3: Dependence of the observed rates of the 
AQT IV/ct-DNA system on the concentration of DNA 
in MES10 buffer, pH 6.4, 0.15 M NaCl at 25 
o
C.   
(A) Fast process; (B) slow process. The fitting assumed 
a site size of 4. 
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Figure 5.4: Dependence of the observed rates of the 
AQT I/ct-DNA system on the concentration of DNA in 
MES10 buffer, pH 6.4, 0.15 M NaCl at 25 
o
C. 
The fitting assumed a site size of 3. 
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Figure 5.5 (S1): Fluorescence spectral titration of ct-DNA with 
3.3 µM AQT I in MES10 buffer, 0.15 M NaCl, pH 6.24 and 25 
oC (λex: 354 nm; λem:536 nm). 
Top: Fluorescence spectra of AQT I with ct-DNA at various 
DNA:AQT I ratios (ri = 0 to 12).  Bottom: The observed change 
in emission intensity at 536 nm as a function of the concentra-
tion of ct-DNA were fitted with equation 2 to obtain an equilib-
rium binding constant and the binding site size.   
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Figure 5.6 (S2): Fluorescence spectral titration of ct-DNA with 
3.3 µM AQT III in MES10 buffer, 0.15 M NaCl, pH 6.24 and 25 
oC (λex: 354 nm; λem:536 nm).   
Top: Fluorescence spectra of AQT III with ct-DNA at various 
DNA:AQT III ratios (ri = 0 to 25).  Bottom: The observed change 
in emission intensity at 536 nm as a function of the concentration 
of ct-DNA were fitted with equation 2 to obtain an equilibrium 
binding constant and the binding site size.   
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Figure 5.7 (S3): Fluorescence spectral titration of ct-DNA with 
3.3 µM AQT III in MES10 buffer, 0.15 M NaCl, pH 6.24 and 25 
oC (λex: 354 nm; λem:536 nm).   
Top: Fluorescence spectra of AQT III with ct-DNA at various 
DNA:AQT III ratios (ri = 0 to 25).  Bottom: The observed change 
in emission intensity at 536 nm as a function of the concentration 
of ct-DNA were fitted with equation 2 to obtain an equilibrium 
binding constant and the binding site size.   
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Figure 5.8 (S4): Dependence of the observed rates of the 
AQT II/ct-DNA system on the concentration of DNA in 
MES10 buffer, pH 6.4, 0.15 M NaCl at 25 
o
C.   
 (A) Fast process; (B) slow process.  The fitting assumed 
a site size of 3.  The faster process was not fitted because 
it was almost completed at the highest concentration of 
DNA and the signal to noise ratio was high.   
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Figure 5.9 (S5): Dependence of the observed rates of 
the AQT III/ct-DNA system on the concentration of 
DNA in MES10 buffer, pH 6.4, 0.15 M NaCl at 25 
o
C.   
(A) Fast process; (B) slow process.  The fitting as-
sumed a site size of 3.  The faster process was not fitted 
because it was almost completed at the highest concen-
tration of DNA and the signal to noise ratio was high.   
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Table 5.1: Kinetic constants for the anthraquinone-DNA interaction 
Ligand K1 (M
-1
) 
    10
4
 
k2 (s
-1
) k-2 (s
-1
) k3 (s
-1
) k-3 (s
-1
) K3 K* (M
-1
)     
    10
4
 
AQT II 
AQT III 
- 
- 
≥630 
≥470 
- 
- 
23 ± 1.7 
19 ± 3.3 
14 ± 1.9 
17 ± 1.1 
2.6  
2.1  
16 ± 1.2 
9.3 ± 0.5 
AQT IV 5.9 ± 0.20 340 ± 16 71 ± 13 21 ± 2.2 19 ± 3.2 2.1  4.0 ± 0.6 
K* is the overall equilibrium binding constant obtained from plotting the change in emission as 
a function of the DNA concentration. 
 
 
5.2.5 Supplementary Information 
Fluorescence Spectroscopy: Data manipulation and plotting was done using the program 
Kaleidagraph version 4.0.  To obtain the binding constant of anthraquinone to DNA, the data was 
fitted to a non-competitive interaction model for nonlinear least-squares optimization of the bind-
ing parameters 
84
: 
 
y = 0.5R {A + B + x – (√((A + B + x)2 – 4Bx))}     eq 2 
 
where R = Rb/n, (Rb is the instrument response sensitivity and is given by the fluorescence of the 
ligand when it is fully bound divided by the total concentration of the ligand; n is the site size); A 
= n/K, (K is the equilibrium binding constant); and B = nLt, (Lt is the total concentration of lig-
and).  The equilibrium binding constant and site size are calculated as K = B/(A*Lt) and n = 
B/Lt.  
 
Kinetics Experiments 
Analysis of AQT I binding to ct-DNA. The dependence of the observed rate constant, kobs, on 
the free DNA site concentration is given by the equation below: 
 
kobs = k1 * F([DNA]) + k-1       eq 3 
 
where k1 is the association rate constant, k-1 is the dissociation rate constant, and F([DNA]) the 
concentration of potential binding sites calculated as outlined by Macgregor et al. 
85
  The calcula-
tion was developed by Jovin and Striker 
76
, based on the McGhee-von Hippel formalism 
75
.  The 
concentration of potential binding sites, F[DNA], depends upon the fraction of sites already oc-
cupied such that 
 
F[DNA] = [DNA]o f(r)       eq 4 
 
where [DNA]o  is the total concentration of potential binding sites in the unoccupied DNA.  Base 
on the McGhee and von Hippel model, f(r) is the exclusion of potential binding sites arising from 
the distribution of the ligands on the DNA and is given by 
 
f(r) = (1-nr)
n
[1-(n-1)r]
1-n       
eq 5 
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where the number of intercalation sites occupied or perturbed (and as such, cannot participate in 
further binding) by a ligand is equal to 2n-1.  At saturating ligand concentrations, the fractional 
DNA occupancy reaches the limit of 1/n. 
Analysis of AQT IV binding to ct-DNA. The kinetic data for the binding of AQT IV to ct-
DNA was analyzed by plotting the observed rate constants, kobs(fast) and kobs(slow), as a func-
tion of the DNA concentration and fitted to equations 6 and 7 as described below: 
kobs(fast) = K1k2 * F([DNA]) / (1 + K1 * F([DNA]))  + k-2   eq 6 
 
and  
 
kobs(slow) = K12k3 * F([DNA]) / (1 + K12 * F([DNA]))  + k-3  eq 7 
 
where K12 = K1(1 + K2).  The overall equilibrium binding constant can be calculated using the 
equation K*(1+ K2(1 + K3).   
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